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ABSTRACT 
Parabens are a group of alkyl esters of p-hydroxybenzoic acid that include 
methylparaben, ethylparaben, propylparaben, butylparaben, and benzylparaben. 
Paraben esters and their salts are widely used as preservatives in cosmetics, toiletries, 
food, and pharmaceuticals. Humans are exposed to parabens through the use of such 
products from dermal contact, ingestion, and inhalation. The extent of the exposure is 
reflected by the frequent detection of these compounds in urine samples in the general 
population. Moreover, parabens have been detected in human serum, milk, placental 
tissues and breast tumor tissues. Parabens have been shown to preserve 
estrogenic/antiandrogenic effects, and can activate peroxisome proliferator-activated 
receptors. Therefore, they are considered endocrine disrupting chemicals (EDC). Here, 
the effects of parabens on adipogenesis in vitro and in vivo were investigated. We report 
that (1) parabens promote adipogenesis (or adipocyte differentiation) in murine 3T3-L1 
cells through activation of nuclear receptor peroxisome proliferator-activated receptor γ 
and glucocorticoid receptor; (2) the adipogenic potency of parabens is increased with 
increasing length of the linear alkyl chain in the following potency ranking order: methyl- 
< ethyl- < propyl- < butylparaben; (3) parabens, butyl- and benzylparaben in particular, 
also promote adipose conversion of human adipose–derived multipotent stromal cells; 
(4) oral feeding of parabens in C57B6/J mice increase adiposity with altered metabolic 
biomarkers; and (5) exposure to parabens enhances adipocyte differentiation, but 
suppresses osteocyte and chondrocyte differentiation from a multipotent stem cell line. 
The results suggest that parabens may contribute to adipogenesis, through enhancing 
differentiation of predetermined preadipocytes, as well as through modulating the 
multipotent stem cells towards adipose lineage.  
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INTRODUCTION 
 Obesity is becoming a global epidemic that affects both adults and children. The 
2012 report from National Health and Nutrition Examination Survey (NHANES) revealed 
that 35.7% of American adults are obesity (body mass index (BMI) > 30) and 68.8% are 
overweight (BMI >25) [1]. Obesity brings about metal problems and increases 
susceptibility to serious health conditions, such as hypertension [2], diabetes [3], and 
certain types of cancer [4]. Chronic low-grade inflammation in adipose tissue has been 
causally linked to insulin resistance, diabetes, and other metabolic complications, thus 
adipose tissue is now recognized as the target for obesity and associated metabolic 
syndromes. 
Recent studies have suggested that obesity might result in part from prenatal and 
neonatal events when energy balance is interrupted. Early life exposure to endocrine 
disrupting chemicals (EDCs) is now considered to be contributing factors for the adverse 
environment that leads to childhood and adult obesity. EDCs are normally used in 
pesticides, plastic products, consumer products, industrial by-products and pollutants. 
Many EDCs, including bisphenol A (BPA), phthalates, organotins etc. have been related 
to increased risk of obesity in human [5-7].  
Parabens are a group of alkyl esters of p-hydroxybenzoic acid that include 
methylparaben, ethylparaben, propylparaben, butylparaben, and benzylparaben. 
Parabens occur naturally in food, they are widely used as preservatives for their 
bactericidal and fungicidal properties in cosmetics, toiletries, pharmaceuticals and food 
[8]. Parabens are detected in human urine, milk, cord blood, and breast tissues [9-12]. 
Health concerns of paraben exposure have been raised since parabens have the ability 
to interact with estrogen receptor [13], androgen receptor [14], and peroxisome 
proliferator-activated receptor  [15]. Studies have shown that paraben exposures are 
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associated with defects in sexual development [16-18], and might play roles in 
development of breast cancer and skin cancer [19,20,8]. 
Given the large-scale use of parabens and comprehensive daily exposure in 
humans, studies on adipogenic effects of parabens are limited. Butylparaben was shown 
to enhance adipocyte differentiation of 3T3-L1 cells, possibly through PPAR activation. 
Concentrations of paraben in urine samples during pregnancy were reported to be 
positively associated with weight growth between third ultrasound exam and birth, as 
well as with birth weight. Methylparaben in particular, was positively related to weight 
and abdominal circumference at 36 months [21]. These results suggest that exposure to 
parabens may contribute to obesity. This dissertation work was to systematically 
investigate the roles of parabens in adipogenesis, both in vitro and in vivo.  
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1.1 Obesity and endocrine disrupting chemicals (EDCs) 
1.1.1 Obesity and associated chronic diseases 
Obesity is becoming a global epidemic that affects both adults and children. It 
was reported in 2012 that 35.7% of American adults are obese (body mass index > 30) 
and 68.8% are overweight (BMI > 25) [1,2]. Obesity not only brings about mental 
pressures including social stigmatization and discrimination, but also increases the 
susceptibility to serious health conditions, such as hypertension [3], diabetes [4], and 
certain types of cancer [5]. 
Obesity is defined as excess of adipose tissue, which is generated from 
increases in adipocyte size and number [6]. It is increasingly recognized that obesity is 
associated with chronic low-grade inflammation in adipose tissue, which has been 
causally linked to insulin resistance, diabetes, and other metabolic complications. 
Chronic inflammation is characterized by proinflammatory cytokine and/or chemokine 
secretion, infiltration of immune cells, and generation of further proinflammatory 
response. Therefore, adipose tissue is now recognized as the key player in obesity and 
associated metabolic syndromes. 
1.1.2 Developmental origin of obesity  
Mounting evidence suggests that adult obesity might result in part from events 
taking place during pregnancy and postnatal development. Ravelli et al. has reported a 
higher incidence rate of obesity in 19-year-old males who had been exposed to the 
1944-1945 Dutch famine during first half of gestation [7]. Another study of 50-year-old 
females who had been exposed to the famine in early gestation found that these women 
had higher BMI and waist circumference [8]. More recent studies showed that people 
with lower birth weight had higher body fat than high-birth-weight group [9,10], implying 
the association between low birth weight and increased obesity risk later in life. 
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Interestingly, higher birth weight was also found to be linked to higher adult BMI [11,12]. 
Therefore, it is postulated that adverse environment in utero or during infancy alters the 
programs of organ development and function, leading to energy imbalance and 
subsequently, obesity in adult life.  
1.1.3 Environmental contribution to obesity: Endocrine disrupting chemicals  
Early life exposure to endocrine disrupting chemicals (EDC) is now considered to 
be contributing factors for the adverse environment that leads to childhood and adult 
obesity. EDCs are chemicals that can disrupt hormonal regulation and endocrine 
homeostasis, resulting in health problems in animals and humans. EDCs are normally 
found in pesticides, plastic products, consumer products, and industrial by-products and 
pollutants.  
Bisphenol A (BPA) is widely used as plasticizers for its cross-linking ability. Early 
life exposure to BPA has been associated with disruption of male and female 
reproductive system [13]. Animal studies found that perinatal exposure to BPA alters 
early adipogenesis and increases body weight [14,15], and BPA exposure prior to 
puberty was able to increase body weight as well [16]. Epidemiological study showed 
that urinary bisphenol A (BPA) concentration in a Chinese population was associated 
with adult obesity and insulin resistance [17].  
Phthalates are mainly used as softeners in paint industry, but could also be found 
in personal-care products and medical devices. Phthalates have been shown to be 
antiandrogenic and can affect reproductive system development in male rodents [18], 
similar results were later confirmed in human studies [19]. Prenatal exposure to 
phthalates is found to be associated with the affected Orientation score and Alertness 
score of neonates [20], and is adversely associated with behavioral domains in children 
age 4 to 9 years that are diagnosed with conduct or attention deficit hyperactivity 
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disorders [21]. Certain phthalates metabolites in urine have been associated with obesity 
in children and adults [22,23].  
Organotins are used to stabilize plastic and as fungicides, rodent repellents and 
in antifouling paints. Animal researches on tributyltin chloride (TBT), one of the well-
known organotins, showed that it affected sexual development and reproductive system 
in both male and female rats [24]. In vitro studies found that organotin compounds 
stimulated differentiation of preadipocytes [25]. Mice studies further showed that in utero 
exposure to organotin compounds increased lipid accumulation in adipose tissue and 
liver, resulting in increased adipose mass in adults [26].  
1.1.4 Mechanisms of metabolic disruption for EDCs 
Hormones function mainly through their receptors. Molecular mechanisms have 
been proposed for the metabolic disrupting effects of EDCs : EDCs act through the 
hormone receptors. 
Peroxisome proliferator-activated receptors  (PPAR is the master regulator for 
adipogenesis and plays important roles in lipid metabolism, and some EDCs are found 
to act as direct PPAR agonists. Organotins are readily measured in house dust and the 
presence was found in human liver and blood [27,28]. Studies showed that organotins 
are PPAR agonists [29,30], and that they activate RXR-PPAR heterodimers primarily 
through the interaction with RXR [31]. Phthalates are normally used as plasticizers and 
found in building materials, medicines and personal care products. Phthalates are found 
to activate PPAR and its target genes in adipocytes, leading to induction of adipocyte 
differentiation [32].  
Glucocorticoid receptor (GR) and thyroid hormone receptor (TR) are two nuclear 
receptors that EDCs can work on. GR is ubiquitously expressed in the cytoplasm of 
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various cell types and plays important roles in metabolism, immune response, growth 
and development. TR regulates metabolism, growth and development. It has been 
reported that BPA and dicyclohexyl phthalate can promote adipogenesis in vitro through 
activation of GR [33]. Several EDCs have been shown to be capable of disrupting 
thyroid function, such as BPA [34], phthalates [35], polybrominated diphenyl esters 
(PBEDs) [36], and polychlorinated biphenyls (PCBs) [37]. 
Estrogen receptors (ERs) are activated by estrogen (17β-estradiol), interruption 
of which could result in reproductive and developmental defects. ERs also play roles in 
many aspects of metabolism, such as glucose and fatty acid metabolism. The most well-
known estrogenic EDC is BPA, known as a synthetic estrogen. As a persistent organic 
pollutant, polychlorinated biphenyls (PCBs) were shown to compete with natural ligand 
for binding to ER, suggesting the ability to interfere with ER signaling [38]. Hydroxylated 
PCB metabolites could inhibit the estrogen catabolism thus increase estradiol 
bioavailability, which might explain the estrogenic effects of PCBs [39] 
1.2 Models of adipogenesis 
Obesity is defined as excessive white adipose tissue (WAT), which is composed 
of a mixture of preadipocytes, adipocytes, stromal vascular tissue, lymph nodes, and 
tissue matrix. Obesity is a result of increased size and/or number of adipocytes. Both 
cellular models and animal models have been instrumental in understanding the 
development of obesity. 
1.2.1 Cellular models of adipocyte differentiation 
Cellular models of adipocyte differentiation have been developed and used to 
understand the molecular mechanisms by which precursor cells are converted into new 
functional adipocytes. The commonly used cellular models for adipogenesis are 3T3-L1 
preadipocytes cell lines and C3H10T1/2 multipotent stem cells. 
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1.2.1.1 3T3-L1 differentiation 
3T3 cells are originally established from primary embryonic fibroblast cells from 
mice [40]. 3T3 cells are subcultured every 3 days, at the rigid density of 3X105 cells/20 
cm2 dish, and 3T3-L1 is one of the cell lines that have been extensively used for 
studying in vitro cellular adipogenesis.  
3T3-L1 cells have a fibroblast-like morphology before differentiation. When cells 
reach confluence, adipocyte differentiation is initiated by treatment of adipogenic 
cocktail. Adipocyte specific genes are induced and lipids are accumulated, and the cells 
adopt a round-shape, lipid-filing morphology at the end of differentiation.  
Upon confluence, the cells are treated with differentiation DMEM containing 10% 
fetal bovine serum, 10 g/ml insulin, 1 M dexamethasone (Dex), and 0.5 mM 3-
isobutyl-1-methylxanthine (MIX) (DMI) for 3 days. The cells are then grown in 
maintenance DMEM containing 10% FBS and 10 µg/ml insulin for an additional 2 days 
and then in DMEM containing 10% FBS until the end of the experiment. Typically, 99% 
of the cells are differentiated into mature adipocytes 8 days following the initiation of 
differentiation.  
1.2.1.2 C3H10T1/2 differentiation 
C3H10T1/2 is a multipotent stem cell line first established in Heidelberger 
laboratory at University of Wisconsin [41]. Derived from C3H mouse embryos, 
C3H10T1/2 cells possess the potential to differentiate into adipocytes, chondrocytes, 
osteocytes or myocytes. 
C3H10T1/2 adipogenic differentiation 
Differentiation of C3H10T1/2 into adipocyte lineage could use different protocols. 
Cheng et al. differentiated the cells in 0.1 M Dex, 50 M indomethacin and 5 g/ml 
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insulin for 14 days [42], while Lee et al. adapted a protocol that is similar to 3T3-L1 
protocol: 2 days in induction medium (1 M Dex, 0.5 mM MIX, 10 g/ml insulin), 6 days 
of maintenance medium (10 g/ml insulin) [43]. Bone Morphogenetic Protein 4 (BMP4) 
and BMP2 have been shown by several research groups to induce commitment of stem 
cells into adipose lineage and promote adipogenic differentiation of C3H10T1/2 cells [44-
46]. Moreover, several cytoskeleton-associated proteins are found important in 
committing the stem cells to adipocyte lineage [45]. Adipocyte specific marker genes can 
be analyzed by the end of differentiation, including FABP4, PPAR, C/EBP, 
adiponectin, fatty acid synthase (FASN).  
C3H10T1/2 chondrogenic differentiation 
Micromass technique modified by Ahrens et al. is used to induce chondrocyte 
differentiation of C3H10T1/2 cells [47]. Specifically, trypsinized C3H10T1/2 cells are 
suspended in Ham’s F12 medium with 10% FBS at a concentration of 107 cells/ml, and 
10 l drop of cell suspension are placed in the center of a well of 24-well tissue culture 
plate. Cells are allowed to adhere in incubator (37°C and 5% CO2) for 2 to 3 h, then 1ml 
of medium containing BMP2 of 100 ng/ml are added to the culture. Medium are 
replenished every three days until the end of the experiment. Chondrocyte specific 
marker genes include link protein, type II collagen, cartilage oligomeric matrix protein 
(COMP), and the cartilage-like matrix can be stained by Alcian blue.  
C3H10T1/2 osteogenic differentiation 
Osteogenic differentiation of C3H101/2 are commonly induced by BMP2 [48], 
BMP7 [49], BMP9[50], or BMP4 [51]. Generally used osteoblast marker genes are 
osteocalcin (OC), alkaline phosphatase (ALP), osteopontin (OPN), bone sialoprotein 
(BSP), and core binding factor alpha 1 (Cbfa1)/Runt-related transcription factor 2 
10 
 
(Runx2). Osteoblast differentiation of mesenchymal stem cells starts from cell 
proliferation to matrix maturation, during which state the ALP expression peaks and 
could be analyzed as a marker for successful differentiation. Then cells undergo matrix 
mineralization when OC, BSP, OPN are expressed. When mineralization is completed, 
calcium deposition is prominent and could be visualized by staining, such as Alizarin 
Red S staining.   
1.2.2 Transcriptional regulation of adipocyte differentiation 
Right after the induction of DMI, growth-arrested preadipocytes undergo several 
rounds of mitotic clonal expansion, which is a permissive state for subsequent 
differentiation [52]. The expression levels of c-fos, c-jun, junB, c-myc and 
CCAAT/enhancer binding protein  and  (C/EBP and ) are increased [53]. C/EBP 
and  are believed to induce Krüppel-like transcription factor 15 (KLF15) [54], which acts 
in concert with the former two factors to mediate the expression of PPAR [55]. PPAR 
peaks at day 3 to day 4, then gradually decreases until day 7 [56,55]. C/EBP was 
thought to be sufficient to initiate adipocyte differentiation, however it is not strictly 
required when ectopic PPAR expression is present [57]. C/EBP becomes detectable 
after 2 days of DMI incubation under regulation of C/EBP and  [58]. PPAR and 
C/EBP are key regulators of adipogenesis, they cross-regulate each other and 
transcriptionally induce expression of a set of adipocyte genes that encode proteins and 
enzymes involved in forming and maintain adipocyte phenotype.  
PPAR 
PPAR is a member of the nuclear hormone receptor family, it has restricted 
pattern of expression in white and brown adipose tissue at adult stage [59]. PPARis the 
master regulator for adipocyte differentiation. Ectopic expression of PPAR enabled 
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nonadipogenic murine fibroblasts to initiate the adipogenic program and become fat cells 
capable of many functions of mature adipocytes [60] and specific PPAR knockdown in 
white adipose tissue induced growth retardation and lipodystrophy in mice [61]. 
PPARis also required for maintenance of mature adipocyte state. Introduction of 
dominant-negative PPAR de-differentiated mature 3T3-L1 adipocytes and resulted in 
lipid loss as well as decreased expression of adipocyte markers [62]. Selective ablation 
of PPAR in mature adipocytes in mice led to death of the cells which were then 
replaced by PPAR-positive adipocytes, implying the important role of PPAR in mature 
adipocyte maintenance.   
PPAR heterodimerizes with retinoid X receptor (RXR) and binds to PPAR 
response element (PPRE) in promoter regions of the target genes, initiating gene 
transcription. PPREs consists of direct repeat 1 (DR1), which was defined by a direct 
repeat of two core motifs (AGGTCA) spaced by one nucleotide [63] and is specific for 
PPAR-RXR heterodimer. Several cofactors have been identified to be in direct contacts 
with PPARs, including corepressors and coactivators. The nuclear receptor corepressor 
(N-CoR) and the silencing mediator for retinoid and thyroid hormone receptor (SMRT) 
are two well-characterized corepressors that repress PPAR transcription activity when 
ligand is not present; which could then be reversed by addition of PPAR ligand 
pioglitazone [64]. Coactivators enhance the transcriptional activation of PPAR-regulated 
genes. Some of the well-known coactivators are steroid receptor coactivator 1 (SRC-1), 
cAMP response element-binding protein (CREB) binding protein (CBP), PPAR 
coactivator 1 and 2 (PGC-1 and -2), PPAR-binding protein (PBP), and androgen 
receptor (AR) –associated protein 70 (ARA70).  
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PPARexpression could be positively regulated by many transcriptional factors, 
including C/EBP and  [65], KLF15 [55,66], Zfp423 [67] and sterol receptor element-
binding protein 1c (SREBP-1c)/adipocyte determination and differentiation dependent 
factor 1 (ADD1) [68]. Some other transcriptional factors can negatively regulate PPAR 
activity, such as KLF2 [69], GATA-2 and GATA-3 [70]. Target genes of PPAR include 
adipokines adiponectin [71], leptin; genes related to lipogenesis and lipid secretion, such 
as stearoyl-CoA desaturase 1 (SCD1), FABP4 [72], FASN, lipoprotein lipase (LPL) [73], 
phosphoenolpyruvate carboxy kinase (PEPCK) [74], and many others. 
GR 
GR is a ubiquitously expressed nuclear receptor that plays roles in metabolism, 
immune response, growth and development. GR activation is necessary for adipocyte 
differentiation, as the synthetic glucocorticoid dexamethasone (Dex) is used in the 
standard adipogenic cocktail, even though excessive amount of glucocorticoids have 
been shown to have adverse effects such as excess visceral fat in patients with 
Cushing’s syndrome [75]. As previously mentioned, PPAR activation is mediated 
downstream of C/EBP and C/EBP, this process also needs the assistance of 
glucocorticoids [76]. GR activation by Dex was shown to prime the preadipocytes for the 
adipocyte fate, which can then be induced into differentiation by PPARligand MIX; but 
the temporal-reversed treatment failed to induce significant differentiation [77].  
GR is localized in cytoplasm when ligand is absent, by association with chaperone 
proteins which binds to the ligand binding domain (LBD) of GR [78]. Binding of GR to 
ligand disassociates chaperone protein, allowing GR subunits homodimerization and 
translocation into nucleus where it binds to glucocorticoid response element (GRE) in 
promoter region of target genes and regulates transcription [79]. GR can also crosstalk 
with other transcriptional factors to repress the target gene expression, such as Nuclear 
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Factor-kappa B (NF-B) and activator protein-1 (AP-1) [80]. GR also interacts with 
coactivators such as SRC-1, SRC-2 (also known as transcriptional 
mediators/intermediary factor 2 (TIF2)) and SRC-3 [81].  
Even though Dex was commonly used as GR ligand to activate GR 
transcriptional activity, it decreased mRNA and protein level of GR by reducing 
transcription and shortening the half-life of GR protein, respectively [82]. Activation of 
GR can increase expression of hormone-sensitive lipase (HSL) and reduce expression 
of LPL, leading to enhanced lipolysis [83]. Preadipocytes factor 1(Pref-1) is a 
transmembrane protein that is abundant in preadipocytes but diminished during 
differentiation, it was found to be suppressed by Dex in 3T3L1 cells [84] and human 
mesenchymal stem cells (MSC) [85], which resulted in induced differentiation. Lipin 1 is 
required for adipocyte differentiation since it converts phosphatidate to diacylglycerol, 
the precursor for triglycerol. Lipin 1 gene expression was found to be up-regulated by the 
glucocorticoids and a GRE site was identified and characterized in lipin 1 promoter 
region [86]. 
Runt-related transcription factor 2 (Runx2) 
Runx2 belongs to the runt-domain gene family, which can bind to DNA, protein 
and ATP [87]. Runx2 is highly expressed in mature osteocytes and has been shown to 
be critical for osteoblast differentiation. Runx2 deficient mice diets after birth because of 
absence of osteoblasts, bone [88], or for a complete lack of ossification [89]. Forced 
expression of Runx2 in nonosteoblastic cells induced expression of principle osteoblast-
specific genes [49].  
Runx2 is also expressed in chondrocytes and increased along with the 
maturation of chondrocytes [90]. Runx2 deficient mice showed disturbed chondrocyte 
differentiation in the skeleton [91] and a lack of hypertrophic chondrocytes in anlagen of 
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the humerus [90], suggesting Runx2 could be a positive regulator for chondrocyte 
differentiation as well.  
Runx2-deficient chondrocytes showed remarkably decreased expression of Pref-
1 and underwent adipocyte differentiation [92], whereas induced expression of Runx2 by 
BMP2 in human marrow stromal precursor cells inhibited late stage adipocyte maturation 
[93]. These data suggest that Runx2 might be an inhibitory factor for adipocyte 
differentiation.  
Since C3H10T1/2 has the potential to differentiate into osteocytes, chondrocytes 
or adipocytes, it is thus of rational sense to speculate that the differentiation into one 
lineage fate would reciprocally suppress the other. Indeed, an inverse relationship have 
been found between the amount of trabecular bone and the adipose tissue in bone 
marrow [94]. Studies in rat marrow stromal cells found that inhibited differentiation of 
adipocytes was concurrent with enhanced differentiation of osteogenic cells [95]. 
Overexpression of PPAR2 stimulated FABP4 expression and fat accumulation in 
murine bone marrow-derived clonal cell lines, while suppressing Runx2 expression and 
osteoblast differentiation [96]. Activation of PPAR by ligand in mesenchymal cells also 
suppressed Runx2-mediated osteoblast differentiation [97]. Runx2 was identified as a 
downstream target of Dex, the downregulation of which was thought to be required for 
3T3-L1 adipogenesis [98]. Lovastatin, a cholesterol-lowering drug, was reported to 
inhibit adipogenesis by suppressing PPAR2 expression while in the meantime enhance 
osteoblast differentiation with increased expression of Runx2 [99]. These results suggest 
that Runx2 might play an important role in deciding the cell fate of multipotent stem cells 
in that it is necessary for osteocyte/chondrocyte differentiation, but suppressive for 
adipocyte differentiation.  
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1.3 Parabens 
1.3.1 Properties of paraben 
Parabens are a group of alkyl esters of p-hydroxybenzoic acid that include 
methylparaben, ethylparaben, propylparaben, butylparaben, and benzylparaben. 
Parabens are generally small colorless crystals or crystalline powders in pure form, and 
are normally stable in air, water and in acidic solutions. Parabens occur naturally in food, 
such as cloudberry, white wine, yellow passion fruit juice and the aerial part of Stocksia 
brahuica [100]. Paraben esters and their salts are widely used as preservatives for their 
bactericidal and fungicidal properties in cosmetics, toiletries, pharmaceuticals and food 
[101].  
1.3.2 Human exposure of parabens 
Human get exposed to parabens through food intake or via cosmetics and drugs. 
The combined consumption of parabens from all sources is estimated to be 76 mg/day: 
1 mg/day from food, 50 mg/day from cosmetics and personal care products, and 25 
mg/day form drugs [102].  
Study of 100 urinary samples from a demographically diverse group with no 
known occupational exposure detected total methylparaben (free and conjugated forms) 
of 0.28 M and 4 M at 50th and 95th percentile, respectively [103]. Methyl- and 
propylparaben were detected in nearly all samples, while other parabens (ethyl-, 
butylparaben) were found in more than half of the samples [103].  
Moreover, parabens have been detected in human milk, placental tissues, and 
breast tumor tissue. Defatted milk samples from cohort studies were used for evaluation 
of presence of parabens, and methyl-, ethyl-, propylparaben were detected [104]. 
Butylparaben were not detected, but it was postulated that butylparaben could possibly 
be present in the milk fat for its lipophilicity [104]. Finding of parabens in embryonic fluid, 
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placenta, fetal liver and fetal carcass after the pregnant rats were exposed to 
ethylparaben and butylparaben suggests the transfer of paraben from placenta to 
fetuses, and suggests that paraben exposure could start as early as embryonic period 
[105]. That higher concentrations of parabens were found in amniotic fluid than maternal 
plasma raised the concerns that concentration of paraben occurs in fetuses and the 
fetuses might be affected at a higher degree by parabens [105]. Towers and colleagues 
did a study on 50 patients and detected methylparaben in blood of 47 mothers (mean 
level 20.41 ng/L) and in 47 paired cord bloods (mean level 36.54 ng/L) [106]. Detection 
of intact parabens in human breast tumors were reported, raising the concerns that 
parabens in cosmetics might increase the incidence of breast cancer [107].  
1.3.3 Pharmacokinetics of paraben 
When orally exposed, almost all parabens are rapidly absorbed from the 
gastrointestinal tract in rats, rabbit, dogs, cats and humans [108-110]. Most absorbed 
parabens are hydrolyzed by esterase in different organs with p-hydroxybenzoic acid 
(PHBA) being the main metabolite; others excreted as glycine, glucuronic acid, and 
sulfuric acid conjugates of PHBA. Metabolized products occur rapidly in urine within 30 
min after ingestion, and majority of the metabolites get cleared in 24 h [111,112]. Even 
after intravenous administration, paraben levels in serum quickly decline and remain low 
[111,112]. Esterases that hydrolyzes parabens are present in subcutaneous fat tissues, 
liver, kidney, and dermal skin. However, the hydrolysis of parabens could be impeded by 
esterases inhibitors that are present in some commonly-consumed food and drinks, such 
as grapefruit juice. Grapefruit juice has been shown to inhibit esterase activities due to 
the presence of many flavonoids [113,114], thus concurrent intake of parabens with 
inhibitory compounds for esterases could probably increase paraben escape from 
hydrolysis so that increased level of parabens are found in circulation.  
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Parabens are largely used in personal products and cosmetics and can be 
absorbed through skin. The dermal permeability of parabens is likely to be affected by 
the type of paraben, the partition coefficient, and other compounds present in the 
product [115,116]. Parabens can be hydrolyzed by cutaneous esterase and thus 
reduced amount of parabens can enter the systemic circulation [117,118].  
1.3.4 Health concerns of paraben exposure 
Despite the wide exposure of paraben to human, the health impacts of paraben 
have been investigated only recently [131,8]. Methyl-, ethyl-, propyl-, butyl-, 
benzylparaben all have been shown to possess estrogenic activity to some extent, and 
the activity increases with increasing length of the side chain [13,132]. Even though the 
ability of parabens for estrogen receptor (ER) binding is lower than some known 
estrogenic ligands and thus are called “weak estrogens”, parabens were able to function 
at the same magnitude as 17-estrodiol in human breast cancer cells when the 
concentration is sufficient [132,13], suggesting that parabens can exert full agonist 
response as estrogen. Parabens were reported to be present in human breast tumors 
[118,12], and comparable concentrations of parabens were later found to be able to 
stimulate proliferation of human breast cancer cells [19], implying the possible 
involvement of parabens in development of breast cancer.  
Parabens have also been shown to activate androgen receptor and possess 
antiandrogenic activity [14]. Animal study revealed alteration of spermatogenesis, 
testosterone secretion, and epididymal weight after repeated oral dosing of propyl- and 
butylparben in post-weaning rats and mice, which might be explained by its estrogenic 
activity and/or antiandrogenic activity that lowered androgen signaling in circulation [16-
18]. Methyl- and ethylparaben didn’t show anti-spermatogenic effects in juvenile rats 
though, levels of testosterone, luteinizing hormone (LH), follicle stimulating hormone 
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(FSH) was not changed either [133]. In humans, urinary parabens were found not to be 
associated with serum hormone levels and semen quality parameters, but positive 
association between butylparaben concentration and  sperm DNA damage were noted 
[134]. 
Since estrogens have influence on skin composition and development, the 
question raises as to whether the estrogenic parabens can affect skin and related aging. 
It was reported that methylparaben decreased cell proliferation and caused changes in 
morphology [135]. Moreover, methylparaben potentiated ultraviolet-B (UVB) induced 
damages in keratinocytes as evidenced by decreased cell viability and enhanced lipid 
peroxidation [20]. Therefore, it has been hypothesized that higher rate of melanoma in 
younger people could possibly be correlated with greater use of paraben-containing 
personal products in this population [8].  
Several studies have shown that parabens activate PPAR, one of the properties 
shared by many EDCs that are associated with metabolic disruption. It was found that 
butylparaben enhanced adipocyte differentiation of 3T3-L1 cells, along with upregulated 
expression and release of leptin, adiponectin and resistin [15]. Concentrations of 
parabens in urine during pregnancy were reported to be positively associated with 
weight growth between third ultrasound exam and birth, as well as with birth weight. 
Concentrations of methylparaben in particular, were positively related to weight and 
abdominal circumference at 36 months [21]. These results suggest that exposure to 
paraben may contribute to obesity.  
In summary, parabens have been shown to interrupt with endocrine system and 
might contribute to obesity. However, there is no direct evidence that has confirmed the 
adipogenic effects of parabens in vitro or in vivo. Due to the widely use of parabens and 
general human exposure, it is necessary to systematically investigate the adipogenic 
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effects of parabens. The specific aims of the current study are: 1) to test whether 
parabens can induce adipocyte differentiation in vitro and what the adipogenic potency 
of various parabens are; 2) to study the molecular mechanisms underlying paraben’s 
potential adipogenic effects; 3) to investigate the adipogenic effects of parabens in vivo; 
and 4) to explore the effects of parabens on modulating multipotent stem cell fate.  
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2.1 Abstract 
Parabens are a group of alkyl esters of p-hydroxybenzoic acid that include 
methylparaben, ethylparaben, propylparaben, butylparaben, and benzylparaben. 
Paraben esters and their salts are widely used as preservatives in cosmetics, toiletries, 
food, and pharmaceuticals. Humans are exposed to parabens through the use of such 
products from dermal contact, ingestion, and inhalation. However, research on the 
effects of parabens on health is limited, and the effects of parabens on adipogenesis 
have not been systematically studied. Here, we report that (1) parabens promote 
adipogenesis (or adipocyte differentiation) in murine 3T3-L1 cells, as revealed by 
adipocyte morphology, lipid accumulation, and mRNA expression of adipocyte-specific 
markers; (2) the adipogenic potency of parabens is increased with increasing length of 
the linear alkyl chain in the following potency ranking order: methyl- < ethyl- < propyl- < 
butylparaben. The extension of the linear alkyl chain with an aromatic ring in 
benzylparaben further augments the adipogenic ability, whereas 4-hydroxybenzoic acid, 
the common metabolite of all parabens, and the structurally related benzoic acid (without 
the OH group) are inactive in promoting 3T3-L1 adipocyte differentiation; (3) parabens 
activate glucocorticoid receptor and/or peroxisome proliferator-activated receptor γ in 
3T3-L1 preadipocytes; however, no direct binding to, or modulation of, the ligand binding 
domain of the glucocorticoid receptor by parabens was detected by glucocorticoid 
receptor competitor assays; and lastly, (4) parabens, butyl- and benzylparaben in 
particular, also promote adipose conversion of human adipose–derived multipotent 
stromal cells. Our results suggest that parabens may contribute to obesity epidemic, and 
the role of parabens in adipogenesis in vivo needs to be examined further. 
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2.3 Introduction 
Parabens are a group of alkyl esters of p-hydroxybenzoic acid that include 
methylparaben, ethylparaben, propylparaben, butylparaben, and benzylparaben (Fig. 
2.1). Paraben esters and their salts are widely used as preservatives in cosmetics, 
toiletries, food, and pharmaceuticals (Darbre and Harvey, 2008). A survey of 215 
cosmetic products in 1995 found parabens in 99% of the leave-on cosmetic products 
and 77% of the rinse-off products (Rastogi et al., 1995). The systemic absorptions of 
parabens into the human body have been reported (Darbre et al., 2004; Ye et al., 2006). 
Intact parabens that escaped from metabolism by esterases from the intestine and skin 
were detected in human urine samples, with methylparaben and propylparaben being 
the most abundant followed by butylparaben. Total methylparaben (free and conjugated 
forms) levels were 43.9 (0.28 µM) and 608 ng/ml (4 µM) at 50th and 95th percentile of 
100 urine samples collected from U.S. adult volunteers who had no known occupational 
exposure (Ye et al., 2006). The detection of parabens in human breast milk has also 
been reported, suggesting constant exposure of parabens early in life (Schlumpf et al., 
2010). 
Despite the wide use and human exposure, the health impacts of parabens have 
been examined only recently (Boberg et al., 2010; Darbre and Harvey, 2008). Both the in 
vitro (Chen et al., 2007; Terasaka et al., 2006; van Meeuwen et al., 2008) and in vivo 
rodent data (Oishi, 2001, 2002) have shown that parabens exert 
estrogenic/antiandrogenic activity, but with estrogenic potency of 3–6 orders of 
magnitude lower than that of 17β-estradiol, although the studies with no effects of 
parabens have also been reported (Shaw and deCatanzaro, 2009). In addition, 
parabens could also act as a thyroid hormone receptor agonist/antagonist and as an  
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Figure 2.1 Chemical structure of parabens, their common metabolite 4-
hydroxybenzoic acid, and structurally related benzoic acid. 
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agonist for peroxisome proliferator–activated receptor (PPAR) (Taxvig et al., 2012). 
Together, these data suggest that parabens are endocrine disrupting compounds (EDC). 
Many environmental EDCs have been suggested to contribute to human obesity 
by interfering with lipid metabolism and/or adipogenesis, hence the term “obesogen” was 
coined (Grün and Blumberg, 2006). However, the effects of parabens on adipocyte 
differentiation (generation of new adipocytes or adipocyte hyperplasia), one of the 
contributing process to obesity, have not been systematically investigated. Murine 3T3-
L1 is the most widely used in vitro cell model for adipocyte differentiation, by which 
fibroblast-like preadipocytes are converted into mature, spherical, and lipid-filled 
adipocytes through a multistage process (Green and Kehinde, 1975). Here we report the 
adipogenic effect of parabens on murine 3T3-L1 cells, as revealed by Oil Red O (ORO)–
stained adipocyte morphology, lipid accumulation, and mRNA expression of specific 
adipocyte marker genes. The abilities of parabens in activating glucocorticoid receptor 
(GR) and peroxisome proliferator–activated receptor, the two established signaling 
pathways in adipocyte differentiation, are also investigated. Lastly, we examine the 
effects of parabens on adipose conversion of human adipose–derived multipotent 
stromal cells (hADSC). 
2.4 Materials and methods 
Reagents 
Cortisone, methylisobutylxanthine (MIX), dexamethasone (DEX), insulin (Ins), 
peroxisome proliferator–activated receptor gamma (PPARγ) agonist rosiglitazone, 
antagonists GW9662, bisphenol A diglycidyl ether (BADGE), and GR antagonist RU-486 
were purchased from Sigma-Aldrich (St Louis, MO). Dimethyl sulfoxide; methyl-, ethyl-, 
butyl-, propyl-, and butylparaben; 4-hydroxybenzoic acid, and benzoic acid sodium salts 
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were all from Acros Organics (Thermo Fisher Scientific, Pittsburg, PA), and 
benzylparaben was from MP Biomedicals (Solon, OH). 
Cell culture, induction of adipocyte differentiation, and paraben treatments. 
Murine 3T3-L1 fibroblasts (ATCC, Manassas, VA) were grown in Dulbecco’s 
modified Eagle’s medium (DMEM) containing 10% calf serum (Hyclone) in 5% CO2, 
37°C environment until they reached confluence. To study the potentiating effects of 
parabens on differentiation induced by glucocorticoids, the standard differentiation 
protocol was modified using a weaker GR agonist cortisone, based on previous studies 
(Kim et al., 2007; Marcolongo et al., 2008; Park et al., 2011). Briefly, on the day of 
reaching confluence (designated as day 0), cells were treated with DMEM containing 
10% fetal bovine serum (FBS, Atlas Biologicals), 0.5 mM MIX, 170 nM Ins, and 5 µM 
cortisone for 3 days (stage 1, day 0–3). The cells were then grown in maintenance 
DMEM containing 10% FBS and 170nM Ins for additional 2 days (stage 2, day 4–5) 
followed by growth in DMEM containing 10% FBS (stage 3, day 6–7) until day 7. hADSC 
were purchased from Zen-Bio (Research Triangle Park, NC) and were grown and 
differentiated according to the supplier’s instructions. Briefly, the cells were seeded and 
grown in 60-mm tissue culture dishes in a preadipocyte medium until confluence. The 
differentiation was initiated with adipocyte differentiation medium for 7 days and 
maintained in adipocyte maintenance medium for additional 7 days. All media used for 
human primary cell culture were purchased from Zen-Bio. 
Various parabens were added in the differentiation media of 3T3-L1 or hADSC. 
 Unless otherwise indicated, the parabens or the vehicle control (DMSO) were 
applied from the initiation and were reapplied at each change of medium for both cell 
types during the whole differentiation process. For the detection of early target genes, 
butylparaben or DMSO was added to the media with or without Dex or the differentiation 
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cocktails (Cortisone, MIX, and Ins; CMI) for indicated time. For the studies of the 
antagonists of GR or PPARγ, the cells were pretreated with the antagonists of PPARγ 
(GW9662 and BADGE) or GR (RU-486) or DMSO for 1h before the cells were cotreated 
with butylparaben or DMSO in the presence of the antagonist. The antagonist was 
reapplied together with butylparaben or the DMSO control at each change of the media. 
ORO staining and quantification. 
To quantify lipid accumulation, differentiated cells were fixed with 4% 
paraformaldehyde overnight and then rinsed with deionized water and stained with ORO 
solution (60% ORO in isopropanol) for 10 min. After staining, the plates were rinsed with 
deionized water and were scanned by a scanjet 3970 scanner (Hewlett-Packard 
Company, Palo Alto, CA). The images of the stained cells were taken by an integrated 
digital camera linked to a Micromaster inverted digital microscope (Thermo Fisher 
Scientific, Waltham, MA). To quantify the staining, the ORO was eluted with 100% 
isopropanol for 10min, and the OD absorbance at 500nm was measured in a Spectronic 
Genesys 5 spectrophotometer (Thermo Fisher Scientific, Waltham, MA). 
RNA preparation and quantitative real-time PCR analysis. 
At indicated times, total RNA was prepared from preadipocytes or adipocytes 
using TRIzol (Invitrogen Corporation, Carlsbad, CA) according to the manufacturer’s 
instructions. Total RNA abundance was quantified using a NanoDrop ND-1000 
Spectrophotometer (NanoDrop Technologies, Wilmington, DE). Reverse transcription 
was carried out using Maxima First Strand cDNA Synthesis kit (Thermo Fisher Scientific, 
Waltham, MA) according to the manufacturer’s instructions. mRNA expression of various 
adipocyte marker genes and loading control 36B4 or 18S were measured quantitatively 
using Absolute Blue QPCR SYBR Green ROX mix (Thermo Fisher Scientific, Waltham, 
MA) or by gene-specific TaqMan gene expression assays (Applied Biosystems, 
49 
 
Carlsbad, CA) (primer sequences and TaqMan probe IDs are provided in the 
Supplemental materials) and were run in a 96-well format using an ABI 7900HT Real-
Time PCR System. Cycle conditions were 50°C 2 min, 95°C 15 min, and then 40 cycles 
of 95°C for 15 s/60°C for 1 min. Relative gene expression was calculated using 2(−∆∆Ct) 
method (Dawson et al., 2012). 
Small RNA interference. 
Silencer Select predesigned and validated siRNA targeting mouse GR or PPARγ 
were purchased from Applied Biosystems (Carlsbad, CA). 3T3-L1 preadipocytes were 
seeded onto six-well plates and transfected with siRNA oligos targeting GR and PPARγ 
or with nontargeting negative control oligos using DeliverX plus system (Affymetrix, 
Santa Clara, CA) according to the manufacturer’s protocol. We have achieved more than 
75% knockdown efficiency with siGR and siPPARγ (data not shown). 
Transfection and reporter gene assays. 
A GR-responsive luciferase reporter construct (the mouse mammary tumor virus 
promoter–driven luciferase reporter MMTV-Luc) was a gift from Dr Vickie Wilson, U.S. 
EPA (Wilson et al., 2002). Murine PPARγ ligand binding domain coupled to the Gal4 
DNA binding domain (DBD) (mPPARγ-Gal4) and a reporter construct containing an 
upstream activating sequence (UAS)–linked luciferase, 4xUAS-TK-luc (TK: thymidine 
kinase), were gifts from Dr Susanne Mandrup (University of Southern Denmark, 
Denmark) (Taxvig et al., 2012). 3T3-L1 preadipocytes stably transfected with MMTV-Luc 
were generated by selecting the stably expressing individual clones with G418 
resistance. For transient transfection, 3T3-L1 preadipocytes were seeded the day before 
and transiently transfected with mPPARγ-Gal4, 4xUAS-TK-Luc, and β-galactosidase (β-
gal) control plasmid (for monitoring the transfection efficiency) with Fugene HD 
transfection reagent (Promega, Madison, WI) according to the manufacturer’s protocol. 
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To further define the activation of paraben on GR, COS-7 cells, which have no or little 
endogenous GR expression, were seeded and transfected with GR or the empty vector 
together with MMTV-Luc and β-gal control plasmid. The cells were treated as indicated 
in the figure legends for 18 h, and cell lysates were prepared and the luciferase and β-
gal activities were measured using Glomax multidetection system (Promega, Madison, 
WI). 
Glucocorticoid receptor competitor assay. 
The competitive binding of parabens for GR was evaluated using the 
PolarScreen GR competitor assay according to the manufacturer’s instructions (Life 
Technologies, Grand Island, NY) using a multimode microplate reader Synergy 2 
(BioTek Instruments, Winooski, VT) (485-nm excitation and 535-nm emission). Briefly, 
full-length human GR is added to a fluorescent glucocorticoid ligand, Fluormone GS1, in 
the presence of test compounds in a 96-well plate. When a test compound competes 
with Fluormone GS1, the GR/Fluormone GS1 complex will not form and Fluormone GS1 
will tumble rapidly, resulting in a low polarization value. The decrease in polarization 
value is used to determine the relative affinity of the test compound(s) for GR. 
Statistical analysis. 
All data were presented as means ± SE in the figures. Each experiment was 
repeated at least three times. Within an experiment, measurements were performed in 
triplicates. Data were log transformed when appropriate for statistical analysis purposes. 
Statistical analysis was performed using SigmaPlot 11.0 (Systat Software, Inc.). One-
way ANOVA was performed followed by multiple comparison tests with Student-
Newman-Keuls Method or Holm-Sidak method to compare with controls to determine the 
differences between the treatment groups or time points. The level of significance was 
set at p < 0.05. 
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2.5 Results 
Parabens Dose-Dependently Promote Murine 3T3-L1 Adipocyte Differentiation 
We first examined the effects of parabens on 3T3-L1 adipocyte differentiation, 
one of the most commonly used in vitro adipogensis models. The standard 3T3-L1 
differentiation cocktail involves using the synthetic glucocorticoid DEX, MIX, and Ins. To 
better explore the potentiating effects of parabens on differentiation induced by 
glucocorticoids, we have chosen to use cortisone, a weaker glucocorticoid as previously 
reported (Kim et al., 2007; Marcolongo et al., 2008; Park et al., 2011). The 
concentrations of parabens were chosen based on the reported human exposure (Ye et 
al., 2006) and previous in vitro studies (Byford et al., 2002; Darbre et al., 2002). 
Confluent 3T3-L1 preadipocytes were induced to differentiate with butylparaben or 
DMSO, in the presence or absence of the differentiation cocktail that is composed of 
CMI. Butylparaben, in the presence of CMI, enhanced the 3T3-L1 adipocyte 
differentiation compared with DMSO, as revealed by the ORO-stained lipid accumulation 
(Fig. 2.2a, left panel), adipocyte morphologies (Fig. 2.2a, right panel), and ORO 
absorbance (Fig. 2.2c, left panel). We further compared the potency of various selected 
parabens and their common metabolite in enhancing the differentiation in the presence 
of CMI. Parabens enhanced 3T3-L1 adipocyte differentiation with the potency that 
increases as the length of the linear alkyl chain increases in the following ranking order: 
methyl- < ethyl- < propyl- < butylparaben. The extension of the linear alkyl chain with an 
aromatic ring in benzylparaben further augmented the adipogenic ability, as revealed by 
ORO-stained lipid accumulation and adipocyte morphologies (Fig. 2.2b) and ORO 
absorbance (Fig. 2.2c, right panel). However, the common metabolite 4-hyrdroxybenzoic 
acid or the structurally related benzoic acid (Fig.2.1) did not have the similar effects 
(Figs. 2.2b and 2.2c, right panel). The effects of various parabens were further confirmed  
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Figure 2.2 Parabens promote 3T3-L1 adipocyte differentiation. 
Confluent 3T3-L1 preadipocytes were induced to differentiate with butylparaben or 
DMSO (a) or with various selected parabens, the common metabolite 4-hydroxybenzoic 
acid or the structurally related benzoic acid (b), in the presence or absence of the 
differentiation cocktail (cortisone 5 µM, MIX 0.5 mM, and insulin 170 nM—CMI) during 
the 7-day differentiation process. Oil Red O (ORO) staining of lipid accumulation (left 
panel) and adipocyte morphology (right panel) and quantification of ORO absorbance (c) 
at D7 are shown. (d) 3T3-L1 preadipocytes were differentiated in the presence or 
absence of increasing doses of selected parabens (1, 10, 100 µM) during the 
differentiation process. Relative mRNA expression of adipocyte markers was analyzed. 
The relative mRNA expression was normalized to 36B4 and expressed as fold of that of 
the 0 µM sample (set at 1) for each paraben. Data are mean ± SE (n = 3). One-way 
ANOVA was performed followed by multiple comparison tests with Student-Newman-
Keuls method for structure-function relationship (c, right panel) or dose response (d) or 
Holm-Sidak method (c, left panel) to compare with the respective control. Different 
letters indicate significant difference (p < 0.05) (c, right panel). The bar indicates the 
dose-dependent responses (d). *, **, p < 0.05, and p < 0.01, respectively. Scale bar = 
127µm. 
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by the dose-dependent induction of mRNA expression of adipocyte marker genes, which 
include the master transcriptional factors, peroxisome proliferator–activated receptor 
(PPAR) γ, and CCAAT-enhancer–binding protein (C/EBP) α, and the genes involved in 
lipid metabolism FABP4 and FAS (Fig. 2.2d). Parabens also dose-dependently induced 
adipocyte-specific adipokine adiponectin mRNA and leptin mRNA (up to 10 µM for 
propyl-, butyl-, benzylparaben) (Fig. 2.2d). No cytotoxicity of parabens at concentrations 
≤ 100 µM was detected by MTT assays in 3T3-L1 cells (data not shown). 
Effects of Exposure Stage to Paraben on 3T3-L1 Adipocyte Differentiation 
Standard 3T3-L1 adipocyte differentiation protocol involves stimulating 
postconfluent cells with differentiation cocktails for 3 days (stage 1, day 0–3) and 
maintaining them in maintenance media for 2 days (stage 2, day 3–5), followed by basal 
media for the remainder 2 days until day 7 (stage 3, day 5–7), during which growth-
arrested confluent preadipocytes reenter the cell cycle for two rounds of division, known 
as mitotic clonal expansion (stage 1), followed by postmitotic intermediate stage (stage 
2) and the terminal stage (stage 3) (Gregoire et al., 1998). To characterize the effects of 
parabens on differentiation process, we attempted to pinpoint the critical stage(s) during 
which parabens promote differentiation. We focused on butylparaben due to both its high 
adipogenic potency (Fig. 2.2b) and wide use. Confluent 3T3-L1 preadipocytes were 
induced to differentiate with the differentiation cocktail CMI in the presence of 
butylparaben or DMSO at indicated time shown in Fig. 2.3a. The exposure of 
butylparaben in both stages 1 and 2 (days 0–5) induced the strongest adipogenic effects 
compared with that in either stage 1 (day 0–3) or stage 2 (day 3–5) alone, as revealed 
by ORO staining (Figs. 2.3b and 2.3c) and mRNA expression of adipocyte-specific 
markers (Fig. 2.3d). No further enhancement of differentiation was observed in 0–7 
group when the cells were exposed to butylparaben for the whole 7-day differentiation  
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Figure 2.3 The effect of exposure stage to paraben on 3T3-L1 adipocyte 
differentiation. 
Confluent 3T3-L1 preadipocytes were induced to differentiate with the differentiation 
cocktail CMI in the presence of butylparaben (100 µM) or DMSO at indicated time shown 
in (a). Oil Red O (ORO) staining of lipid accumulation (b), quantification of ORO 
absorbance (c), and relative mRNA expression of adipocyte markers at D7 (d) are 
shown. The relative gene expression was normalized to 36B4 and expressed as fold of 
DMSO 0–3 samples (set at 1). Data are the mean ± SE (n = 3). One-way ANOVA was 
performed followed by multiple comparison tests with Student-Newman-Keuls method to 
compare among different treatment groups. Different letters indicate significant 
difference (p < 0.05). 
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process. The presence of butylparaben in stage 1 was more effective than the presence 
in stage 2 in promoting differentiation. The exposure of butylparaben in stage 3 (day 5–
7) had minimal effects, compared with the DMSO group. These results suggest that 
butylparaben may modulate the early events of the differentiation process to promote 
differentiation. 
Parabens Activate GR in 3T3-L1 Preadipocytes 
Many EDCs have been shown to induce adipocyte differentiation in vitro through 
activation of GR (Sargis et al., 2010). Therefore, we tested whether parabens have 
glucocorticoid-like activity using a GR-responsive luciferase reporter (MMTV-Luc). 3T3-
L1 preadipocytes stably transfected with MMTV-Luc were treated with selected 
parabens for 18h. Parabens activated MMTV promoter mediated–luciferase activities, 
and the potency increased as the length of the linear alkyl chain increased in the 
following ranking order: methyl- < ethyl- < propyl- < butylparaben in 3T3-L1 
preadipocytes (Fig. 2.4a). The extension of the linear alkyl chain with an aromatic ring in 
benzylparaben further increased the ability to activate the reporter. To better define the 
interaction of paraben with GR, COS-7 cells, known to have no or little endogenous GR 
expression (Charmandari et al., 2005; Danielsen et al., 1989; Xu et al., 1996), were 
transfected with full length of GR or the empty vector, together with MMTV-Luc and the 
control plasmid -gal. Transfection of full-length GR, but not the empty vector, conferred 
the effects of butylparaben alone and the synergistic effects on glucocorticoid ligand 
Dex-induced GR activation (Fig. 2.4b), demonstrating the activation of GR by the 
paraben. 
To confirm the activation of GR by parabens, we further examined the effects of 
butylparaben on mRNA expression of the known target gene of GR, lipin 1 (Zhang et al., 
2008), in 3T3-L1 cells. Lipin 1 was initially identified as a phosphatidic acid phosphatase- 
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Figure 2.4 Parabens activate GR reporter and target gene without directly binding 
to, or modulating, the ligand binding of the receptor. 
(a) 3T3-L1 preadipocytes stably transfected with MMTV-Luc were seeded and treated 
with various parabens (100 µM) for 18h. (b) COS-7 cells were seeded and transfected 
with the empty vector or the full length of GR, with MMTV-Luc reporter and β-gal control 
plasmid for 24h before the cells were treated with butylparaben (100 µM) or DMSO in 
the presence or absence of Dex (1 µM) for 18h. The reporter gene assays were 
performed. Luciferase activities were normalized with the β-gal activities. (c) Confluent 
3T3-L1 preadipocytes were treated with butylparaben (100 µM) or DMSO in the 
presence or absence of Dex (1 µM) for 4h. (d) 3T3-L1 cells were transfected with siRNA 
targeting GR (siGR) or nontargeting control (siCON) for 24h. The cells were then treated 
with butylparaben or DMSO in the presence of Dex for 4h. The relative gene expression 
was normalized to 36B4 and expressed as fold of the respective control (set at 1). (e, f) 
Human GR/fluormone complex was incubated with various parabens (100 µM), Dex (1 
µM), or cortisone (5 µM) (e) or with butylparaben (10, 100 µM) in combination with Dex 
(0.1 and 0.5µM) (f). Polarization was measured. Data are mean ± SE (n = 3). One-way 
ANOVA was performed followed by multiple comparison tests with Student-Newman-
Keuls method for structure-function relationship (a) or to compare among different 
groups (b) or Holm-Sidak method (c–f) to compare with the respective control. *, **, p < 
0.05, and p < 0.01, respectively; N.S., not significant. 
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1 enzyme, which catalyzes the conversion of phosphatidate to diacylglycerol, the 
immediate substrate for the synthesis of triacylglycerol and other phospholipids (Han et 
al., 2006). The upregulation of lipin 1 mRNA by Dex (Zhang et al., 2008) is an early 
event during adipocyte differentiation. Stimulation by butylparaben in the presence or 
absence of Dex for 4h induced lipin 1 mRNA (Fig. 2.4c). Consistently, the upregulation 
of lipin 1 mRNA by butylparaben was attenuated by transfection of siRNA targeting GR, 
but not the negative control (Fig. 2.4d). 
EDCs have been shown to modulate GR activity by competing the ligand binding 
to the receptor (Gumy et al., 2008; Johansson et al., 1998, 2005). To determine whether 
parabens can bind to the ligand binding domain of GR, we performed the competitive 
binding assays of parabens with the full-length human GR using PolarScreen GR 
competitor assays in which the complex of human GR and a tracer glucocorticoid 
(Fluormone GS1) was incubated with various parabens. No competitive binding of 
parabens to GR was detected (Fig. 2.4e), as revealed by no decreases in polarization 
value. In contrast, the positive control Dex (1 µM) and Cort (5 µM) showed competitive 
binding to the GR, as revealed by the decrease in polarization (Fig. 2.4e). To determine 
whether parabens may be an allosteric modulator of the ligand binding of GR, we 
performed the competitive binding assays with increasing doses of butylparaben in the 
presence of low concentrations of Dex (0.1 and 0.5 µM). As shown in Fig. 2.4f, 
butylparaben did not appreciably enhance the binding of Dex to the GR at the tested 
concentrations, as revealed by no further decrease in the polarization values of Dex. 
Similar results were observed with methylparaben and benzylparaben (data not shown). 
These results suggest that parabens may not compete for, or allosterically modulate, the 
ligand binding of GR. 
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Parabens Activate PPAR in 3T3-L1 Preadipocytes 
Paraben also has been recently reported to act as a PPARγ agonist (Taxvig et 
al., 2012). We tested the effects of parabens on PPARγ transactivation in 3T3-L1 
preadiocytes using the PPARγ ligand binding domain coupled with the DBD of Gal4 and 
a reporter containing a UAS-linked luciferase, 4xUAS-TK-luc. As shown in Fig. 2.5a, 
parabens transactivated PPARγ, and the potency increased as the length of the linear 
alkyl chain increased in the following ranking order: methyl- < ethyl- < propyl- < 
butylparaben. However, benzylparaben, which has the most potent adipogenic effects, 
did not significantly activate PPARγ, which may suggest differential mechanisms 
underlying the adipogenic effects of various parabens. 
To confirm the activation of paraben on PPARγ, we further examined the effects 
of butylparaben on mRNA expression of the known target genes of PPARγ. We have 
focused on PPARγ target gene perilipin (Arimura et al., 2004) and FABP4 (Frohnert et 
al., 1999; Martin et al., 2000) in 3T3-L1 cells. Perilipin belongs to a family of proteins 
found on the surface of lipid droplets in adipocytes and has been suggested to act as 
regulator of lipolysis (Greenberg et al., 1993; Souza et al., 1998). FABP4 is an 
adipocyte-specific fatty acid binding protein that controls the transport of fatty acids in 
adipocytes (Martin et al., 2000). Stimulation of butylparaben in the presence or absence 
of the differentiation cocktail (CMI) for 24h induced perilipin and FABP4 mRNA, 
compared with the DMSO group (Fig. 2.5b). Consistently, the upregulation of the mRNA 
expression of perilipin and FABP4 by butylparaben was attenuated by transfection of 
siRNA targeting PPARγ, but not the negative control (Fig. 2.5c). These results further 
support the fact that the effects of parabens are mediated through PPARγ. 
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Figure 2.5 Parabens activate PPARγ reporter and target genes. 
(a) 3T3-L1 preadipocytes were transiently transfected with mPPARγ-Gal4, 4xUAS-TK-
luc, and β-gal for 24h and treated with various parabens (100 µM) for 18h. The reporter 
gene assays were performed. Luciferase activities were normalized with β-gal activities. 
(b) Confluent 3T3-L1 cells were treated with butylparaben (100 µM) or DMSO in the 
presence or absence of the differentiation cocktail CMI for 24h. (c) 3T3-L1 cells were 
transfected with siRNA targeting PPRARγ (siPPARγ) or nontargeting control (siCON) for 
24h. The cells were treated with butylparaben or DMSO in the presence of CMI for 
further 24h. The relative gene expression was normalized to 36B4 and expressed as fold 
of the respective control (set at 1). Data are mean ± SE (n = 3). One-way ANOVA was 
performed followed by multiple comparison tests with Student-Newman-Keuls method 
for structure-function relationship (a) or Holm-Sidak method (b, c) to compare with the 
respective control. *, **, p < 0.05 and p < 0.01, respectively. 
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Antagonizing GR or PPARγ Suppresses the Adipogenic Effects of Parabens 
To further confirm whether the adipogenic effects of parabens are through 
activation of GR or PPARγ, the effects of PPARγ and GR antagonists were investigated. 
3T3-L1 cells were pretreated with the antagonist of GR (RU-486), PPARγ (GW9662 and 
BADGE), or the vehicle control DMSO for 1 h before the cells were cotreated with 
butylparaben or DMSO and the antagonist in the presence of the differentiation cocktail 
(CMI). The antagonist was reapplied together with butylparaben at each change of the 
media during the differentiation process. PPARγ antagonists GW9662 and BADGE and 
GR antagonist RU-486 all significantly suppressed butylparaben’s effects on adipocyte 
differentiation, as revealed by attenuated ORO-stained lipid accumulation (Fig. 2.6a) and 
mRNA expression of specific marker genes (Fig. 2.6b). 
We next asked the question whether paraben can replace the glucocorticoid in the 
standard differentiation cocktail (Dex + MIX + Ins). Confluent 3T3-L1 preadipocytes were 
induced to differentiate with butylparaben or DMSO in the presence of medium only, MIX 
+ Ins (without Dex), or the standard differentiation cocktail (Dex + MIX + Ins). In the 
presence of MIX and Ins (without Dex), butylparaben was sufficient to stimulate 3T3-L1 
adipocyte differentiation to a level that is comparable to that induced by the standard 
differentiation cocktail (Dex + MIX + Ins), as revealed by ORO-stained lipid accumulation 
(Figs. 2.7a and 2.7b) and mRNA expression of adipocyte-specific markers, compared 
with the respective control (Fig. 2.7c). As expected, butylparaben significantly enhanced 
the differentiation induced by the standard differentiation cocktail (Dex + MIX+ Ins), 
demonstrating the synergistic effects of paraben on adipogenesis (Figs. 2.7a–c). 
Butylparaben alone in the absence of MIX and Ins was not sufficient to enhance 
differentiation (Figs. 2.7a–c). 
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Figure 2.6 The antagonists of GR and PPARγ attenuate paraben-induced 3T3-L1 
differentiation. 
Confluent 3T3-L1 preadipocytes were induced to differentiate with butylparaben (100 
µM) or DMSO in the presence of the differentiation cocktail (CMI), with or without the GR 
antagonist RU-486 (10 µM), the PPARγ antagonist GW9662 (20 µM), or BADGE (50 
µM) during the process. Quantification of Oil Red O absorbance (a) and relative mRNA 
expression of adipocyte markers (b) are shown. The relative gene expression was 
normalized to 36B4 and expressed as fold of the DMSO-treated samples (set at 1). Data 
are mean ± SE (n = 3). One-way ANOVA was performed followed by multiple 
comparison tests with Holm-Sidak method to compare the antagonist with the respective 
control. *, **, p < 0.05 and p < 0.01, respectively. 
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Figure 2.7 Paraben acts as a glucocorticoid-like compound to promote 3T3-L1 
adipocyte differentiation. 
Confluent 3T3-L1 preadipocytes were induced to differentiate with butylparaben or 
DMSO in the presence of the medium only, MIX + Ins (without Dex), or the standard 
differentiation cocktail (Dex + MIX + Ins). Oil Red O (ORO) staining of lipid accumulation 
(a), quantification of ORO absorbance (b), and relative mRNA expression of adipocyte 
markers (c) are shown. The relative gene expression was normalized to 36B4 and 
expressed as fold of the respective control (set at 1). Data are mean ± SE (n = 3). One-
way ANOVA was performed followed by multiple comparison tests with Student-
Newman-Keuls method. Different letters indicate significant difference (p < 0.05) among 
the butylparaben-treated groups. **, p < 0.01 versus the respective control. 
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Effects of Parabens on Adipose Conversion of hADSC 
To further explore the adipogenic effects of parabens in human cells, we 
evaluated the effects of parabens on adipose conversion of hADSC. As butyl- and 
benzylparaben caused cell toxicity when used at 100 µM (MTT assays, data not shown) 
in hADSC cells, we differentiated hADSC with various parabens at 50 µM or DMSO in 
the presence of the differentiation media, which include Dex, MIX, Ins, and PPARγ 
agonist, for 7 days. The cells were then maintained in the adipocyte maintenance media 
with parabens or DMSO for additional 7 days until the cells were fully differentiated into 
adipocytes. Among the tested parabens, butyl- and benzylparaben promoted lipid 
accumulation as early as day 3 and continued throughout the differentiation process, as 
revealed by the lipids-containing cell morphologies (Fig. 2.8a) and upregulation of 
adipocyte-specific lipid binding protein FABP4 mRNA (Fig. 2.8b). On day 14, 
benzylparaben showed the most potent adipogenic effects, as revealed by upregulation 
of mRNA expression of adipocyte marker genes (FABP4, FAS, and adiponectin), in 
addition to the lipid-filled adipocyte morphology (Fig. 2.8b). Moreover, all parabens 
tested significantly suppressed leptin mRNA on day 14. At 50 µM, butylparaben did not 
induce mRNA expression of adipocyte marker genes except for FABP4 in hADSC cells. 
Further dose-response analysis of butylparaben (1, 10, 50 µM) showed that 
butylparaben at 1 µM had the strongest adipogenic effects, as revealed by the lipid-filled 
adipocyte morphology (Fig. 2.8a) and upregulation of mRNA expression of adipocyte 
marker genes (PPARγ, C/EBPα, FABP4, FAS, and adiponectin) (Fig. 2.8c), whereas 
other parabens showed no significant effects at either 1 or 10 µM concentrations (data 
not shown). 
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Figure 2.8 Parabens promote adipocyte conversion of hADSC. 
hADSC cells were differentiated with various parabens (50 µM) (a, b) or increasing 
doses of butylparaben (1, 10, 50 µM) (a, c) in the presence the differentiation media. 
Human adipocyte morphologies (a) and mRNA expression of adipocyte-specific markers 
(b and c) are shown. The relative gene expression was normalized to 18S and 
expressed as fold of the DMSO-treated samples (set at 1). Data are mean ± SE (n = 3). 
One-way ANOVA was performed followed by the tests with Holm-Sidak method to 
compare various parabens or doses with the DMSO group. *, **, p < 0.05, and p < 0.01 
versus the DMSO control, respectively. Scale bar = 127 µm. 
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Figure 2.8 Continued 
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2.6 Discussion 
As preservatives, parabens have been widely used in personal care products, 
pharmaceuticals, and food and beverage processing. The most common parabens used 
in cosmetic products are methylparaben, propylparaben, and butylparaben; and more 
than one paraben is often used in a single product (US FDA, 2007). In Europe, up to 
0.4% for one ester or a maximal of 0.8% for a mixture of paraben esters is allowed in 
finished products (EU Cosmetics Directive 76/768/EEC). In the United States, the 
Cosmetic Ingredient Review (CIR) reviewed the safety of parabens in 1984 and 
concluded that they were safe to use in cosmetic products at levels up to 25%. Although 
the CIR began to reopen the safety assessments of parabens in 2003 and 2005, there 
have been no changes to the original conclusion that parabens are safe as used in 
cosmetics (U.S. FDA, 2007). As a result, there continues to be a constant exposure of 
parabens from a wide variety of sources (Darbre and Harvey, 2008). 
Despite the wide use and constant daily human exposure, the health impact of 
parabens has just begun to be examined (Boberg et al., 2010; Darbre and Harvey, 
2008). Recent studies have suggested that parabens are EDCs with estrogenic/ 
antiandrogenic activities (Chen et al., 2007; Oishi, 2001, 2002; Shaw and deCatanzaro, 
2009; van Meeuwen et al., 2008). Here, we report, for the first time, the adipogenic 
effects of parabens in both murine 3T3-L1 and hADSC, the two most commonly used in 
vitro adipogenesis models. Our studies show that parabens, butylparaben and 
benzylparaben in particular, but not the common metabolite 4-hydroxybenzoic acid or 
structurally related benzoic acid, promote adipogenesis in vitro in both systems. 
Moreover, we show that parabens activate GR (without directly binding to or modulating 
the ligand binding of GR) and/or PPARγ, thereby promoting adipogenesis. 
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Several recent studies have demonstrated the potentials of parabens entering 
into human body in intact and unmetabolized forms. Traditionally, it was believed that 
parabens are rapidly absorbed from gastrointestinal tract or intact skin followed by ester 
linkage hydroxylation and glucuronidation or sulfation before being excreted from the 
urine, which partially contributes to their low toxicity and broad “inertness” (Darbre, 
2004). However, Ye et al. have reported the detection of free, unconjugated parabens in 
majority of urine samples (99% and 96%, for methyl and propylparaben; 58%, 69%, and 
39% for ethyl, butyl, and benzylparaben, respectively) collected from humans with no 
known occupational exposures (Ye et al., 2006). Intact parabens were also detected in 
normal human placenta and breast tumors (Darbre et al., 2004). Moreover, Janjua et al. 
have reported the detection of butylparaben in serum of human volunteers who were 
exposed for 1 week to a cosmetic formulation containing butylparaben and phthalates 
(Janjua et al., 2007). In fact, the insufficiency of skin esterase to hydrolyze all paraben 
esters to completion was revealed by the rapid absorption of parabens through the skin 
even with a single dose of body care product into the human body, and permeation of 
parabens through human skin increases with repeated doses ex vivo (El Hussein et al., 
2007). 
Human exposure to parabens appears to be influenced by many other factors 
(Bando et al., 1997; Soni et al., 2005). The common food components such as 
flavonoids in grapefruit juice and grape seed extract are esterase inhibitors and have 
been shown to effectively increase the bioavailability of ester pro drugs into the 
circulation without being extensively metabolized (Li et al., 2007). Moreover, the 
presence of penetration enhancers or various surfactants found in personal care 
products can alter the penetration of parabens and consequently their absorption 
(Esposito et al., 2003; Komatsu et al., 1986). Furthermore, coexposure to various ester 
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pesticides and ester pharmaceuticals can also enhance the bioavailability of parabens in 
the body of the individual as they compete with parabens for esterase (Li et al., 2007). 
Lastly, interindividual differences in dermal metabolic capacities among humans do exist 
(Calafat et al., 2010; Jewell et al., 2007). Overall, with wide interindividual variability in 
exposure levels, these studies support the physiological relevance of our results with 
intact parabens. 
We have attempted to address the molecular mechanisms by which parabens 
elicit the adipogenic effects. Our results show that the adipogenic potential of paraben 
increases as the length of linear alkyl chain increases, and the extension of the linear 
alkyl chain with an aromatic ring in benzylparaben further augments the adipogenic 
ability. The results are consistent with the abilities of parabens to activate GR-responsive 
reporter (Fig. 2.4a). GR plays a critical role in adipocyte differentiation. GR signaling is 
important for inducing the expression of C/EBPs, which, in turn, increases PPARγ 
expression, the master regulator of adipogenesis (Farmer, 2006; Gregoire et al., 1998). 
The activation of GR by parabens has been further supported by the fact that 
transfection of COS-7 cells (with no or low endogenous GR expression) with full-length 
GR expression plasmid confers the GR activation by butylparaben with or without Dex 
(Fig. 2.4b). Moreover, butylparaben induces mRNA expression of the known GR target 
gene lipin 1 (Zhang et al., 2008) both in the presence and absence of Dex, and the 
knockdown of GR by siRNA attenuates the upregulation of lipin 1 mRNA by 
butylparaben (Figs. 2.4c and 2.4d). Furthermore, the GR antagonist RU-486 attenuates 
the adipogenic effects of butylparaben (Fig. 2.6). Overall, these results suggest that the 
effects of butylparaben are mediated through the GR signaling pathway. 
EDCs have been shown to modulate GR activity by competing with the ligand 
binding to the receptor. Lund and associates reported that tolylfluanid and 
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methylsulfonyl-PCBs competed with glucocorticoid for binding to GR (Johansson et al., 
2005). However, GR competitor assays showed that there was no competitive binding of 
GR by the parabens, unlike DEX or cortisone (Fig. 2.4e). To this end, some EDCs have 
also been shown to alter the ligand binding affinity through allosteric effects on the 
receptor. Dibutyltin, one of the organotins used as stabilizer in the production of polyvinyl 
chloride plastics, can inhibit GR activation through insertion at an allosteric site near the 
steroid-binding pocket (Gumy et al., 2008). It is possible that parabens may enhance the 
binding of glucocorticoids through modulation of the ligand-binding domain of GR. 
However, further GR competitor assays with the paraben and Dex added together did 
not support this possibility, suggesting that parabens may not modulate the ligand 
binding of GR (Fig. 2.4f). On the other hand, some EDCs have been shown to modulate 
glucocorticoid activation by modulating the glucocorticoid metabolizing enzymes: 11β-
hydroxysteroid dehydrogenase-1 and-2, which catalyze the conversion between 
cortisone and cortisol (Draper and Stewart, 2005). Although our preliminary results show 
the induction of 11β-hydroxysteroid dehydrogenase-1 by parabens as the differentiation 
proceeds, the effects of parabens on 11β-hydroxysteroid dehydrogenase-1 (11β-HSD1) 
mRNA expression do not seem to fully explain the results of parabens on GR activation 
and adipogenesis as there is no clear trend of induction of 11β-HSD1 mRNA with 
increasing length of the linear alkyl chain of parabens (data not shown). Moreover, even 
with charcoal-stripped serum with minimal endogenous glucocorticoids, parabens still 
activate GR in GR-responsive reporter assays (data not shown), and butylparaben can 
substitute DEX to induce marked differentiation when it is combined with MIX and Ins 
(Fig. 2.7), suggesting that 11β-HSD1 mRNA upregulation may not be the main 
mechanism underlying the adipogenic effects of parabens. Further studies are needed to 
elucidate the mode of action of parabens on GR, thereby promoting adipogenesis. 
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Consistent with the recent report by Taxvig et al. (2012), our results show that 
parabens transactivate PPARγ (Fig. 2.5a). Consistently, we show that butylparaben 
induces the expression of target genes (e.g., perilipin and FABP4), and the upregulation 
of the target genes by butylparaben is attenuated by siRNA targeting PPARγ (Figs. 2.5b 
and 2.5c). Moreover, PPARγ antagonists (GW9662 and BADGE) suppress the 
adipogenic effects of butylparaben in 3T3-L1 cells (Fig. 2.6). Interestingly, 
benzylparaben, which shows the potent adipogenic effects, does not activate PPARγ in 
the transactivation assay. Why benzylparaben does not transactivate PPARγ, yet still 
has a strong adipogenic effect, is currently unknown. However, it has been reported that 
some EDCs induce 3T3-L1 adipocyte differentiation in a PPARγ-independent manner 
(Chamorro-Garcia et al., 2012). We have observed that benzylparaben induces the 
greatest activation of GR as assessed by MMTV promoter–linked luciferase (Fig. 2.4a). 
Therefore, it is possible that the adipogenic effects of parabens may be mediated 
through multiple nuclear receptors. 
Taken together, our results suggest that parabens may activate multiple nuclear 
receptors, thereby promoting adipogenesis. Future studies are necessary to reveal 
parabens’ effects on other endogenous adipogenic signals. 
Information generated from preadipose cell lines and primary preadipocytes 
suggests that the committed preadipocytes have to go through growth arrest and mitotic 
clonal expansion, leading to the clonal amplification of committed cells in early stage, to 
intermediate stage and then to terminal differentiation, when the cells take on 
morphology and functions of mature adipocytes (Gregoire et al., 1998). The fact that 
parabens show more potent adipogenic effects when treated at early stage (stage 1, day 
0–3) suggests that parabens may affect these early events necessary for differentiation. 
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Further studies are needed to elucidate the mechanisms of parabens’ action during early 
stage of adipocyte differentiation. 
In addition to the adipogenic effects, parabens are also shown to modulate 
mRNA expression of adipokines, adiponectin and leptin during differentiation. Parabens 
upregulate adiponectin mRNA expression in both 3T3-L1 adipocytes and the primary 
adipocytes derived from human adipose multipotent stromal cells, consistent with the 
potentiating effects of parabens on differentiation. In contrast, parabens suppress leptin 
mRNA in human primary adipocytes (Fig. 2.8b) but differentially increase leptin mRNA in 
3T3-L1 adipocytes (Fig. 2.2d). However, the reasons for parabens inducing differential 
effects on leptin mRNA in the two cell models are currently unknown. Leptin plays 
important roles in regulating food intake and metabolic and endocrine functions 
(Stofkova, 2009). It has been reported that rats exposed to butylparaben at 100-mg/kg 
body weight in utero from gestation day (GD) 11–20 had low serum leptin levels at GD 
21, compared with the controls, suggesting a role of butylparaben in the developmental 
programming of the metabolic system (Boberg et al., 2008). 
In summary, parabens, butylparaben and benzylparaben in particular, promote 
adipogenesis in vitro in both murine 3T3-L1 cells as well as hADSC. The adipogenic 
effects of parabens are mediated through GR and/or PPARγ. Future studies are required 
to delineate the molecular mechanisms by which parabens act on adipogenesis in vitro 
and to define the parabens’ action in vivo.  
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CHAPTER III 
POST-WEANING EXPOSURE TO PARABENS INCREASE ADIPOSITY AND 
PROMOTE DIFFERENTIATION OF MULTIPOTENT MESENCHYMAL STEM 
CELLS TOWARDS ADIPOSE LINEAGE 
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A version of this chapter will be submitted by Pan Hu, Rebekah Kennedy, Xin Chen, 
Jiangang Chen, and Ling Zhao under the title, “Post-weaning Exposure to Parabens 
Increase Adiposity and Promote Differentiation of Multipotent Mesenchymal Stem Cells 
Towards Adipose Lineage”. 
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3.1 Abstract 
Paraben esters and their salts are widely used as preservatives in cosmetics, 
personal care products, pharmaceuticals, and foods. Human exposure to parabens has 
been confirmed. It has been reported that parabens promote adipogenesis in vitro. In 
this study, we investigated the effects of post-weaning exposure to parabens 
(methylparaben and butylparaebn) on metabolic biomarkers in female obesity prone 
C57B6/J mice fed with a chow diet with low phytoestrogens or a high fat diet (45% kcal 
from fat). We also examined the effects of parabens on modulating cell fate of a 
multipotent stem cell line C3H10T1/2. Methylparaben exposure by daily oral gavage 
(100 mg/kg/day) increased body weight, body fat mass, adiposity, and serum 
adiponectin and leptin levels in mice fed with the chow diet, but not in mice fed with the 
high fat diet. Butylparaben exposure only increased fasting glucose levels in mice fed 
with the chow diet, but had no effects in mice fed with the high fat diet. Moreover, both 
parabens modulated adipogenic, osteogenic, and chondrogenic differentiation of 
C3H10T1/2 cells in vitro. Butylparaben markedly promoted adipogenic differentiation, but 
suppressed osteogenic and chondrogenic differentiation whereas methylparaben 
showed similar effects but to a much less extent. Collectively, these results suggest that 
parabens, methylparaben in particular, increase adiposity under the chow diet, possibly 
through modulation of multipotent stem cell fate towards adipose lineage at the expense 
of osteoblast and chondrocyte lineage. Our studies have provided rationales to study 
paraben exposure at a range of doses and during the perinatal period, a presumably 
more sensitive window of development, in the future. 
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3.3 Introduction 
Paraben esters and their salts are widely used as preservatives in cosmetics, 
personal care products [1], pharmaceuticals, and foods [2]. Systemic human exposure to 
parabens has been confirmed; parabens have been detected in human serum [3,4], milk 
[5], placental tissues [6], seminal plasma [4], and breast tumors [7]. The extent of this 
exposure is reflected by the frequent detection of free and conjugated forms of parabens 
in urine samples in the general population [8-10].  
 The detection of parabens in human breast milk and placenta [6,5] has raised the 
concerns about impact of perinatal exposure to parabens on human health. It has been 
reported that when pregnant rats were exposed to ethylparaben and butylparaben, the 
concentrations of both free and conjugated parabens were higher in the embryonic fluid, 
fetal carcass and liver than in the maternal plasma, indicating that parabens can cross 
the placenta, cumulating in the fetuses [11]. 
 The health implications of paraben exposure have mostly been from in vitro and 
animal studies. Using human reporter cell lines, parabens, including butyl-, propyl-, and 
ethylparaben, can activate estrogen receptors alpha and beta (ERα and ERβ) [12]. At 
concentrations detected in the human breast tumors, parabens enhanced colony growth 
of a human breast cancer cell line, suggesting a role of parabens in the development of 
breast tumor [13]. Exposure to parabens have been shown to be uterotrophic in 
immature or ovariectomized female mice and rats [14] and lead to decreased sperm 
counts and testosterone levels in male mice and rats [15-17], suggesting that parabens 
are estrogenic/antiandrogenic in vivo, although the interpretation of results are still under 
debate [18].  
 Several studies [19-21] have shown that parabens also activate nuclear 
receptors, PPAR in particular, which is one of the properties shared by many known 
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EDCs with metabolic disruption capabilities [22,23]. Indeed, we have reported [20] and 
later confirmed by others [21] that parabens promote adipocyte differentiation of 3T3-L1 
cells and primary culture derived from human adipose tissue and that the effects may be 
mediated through activation of PPAR and/or glucocorticoid receptor (GR). Recently, a 
study of 520 mother-son pairs from French EDEN cohort reported that concentrations of 
measured parabens (methyl-, ethyl-, propyl-, and butylparaben) in the mother’s urine 
during pregnancy were positively associated with weight growth between the third 
ultrasound exam and birth, and with birth weight. The concentrations of methylparaben 
were also positively related to weight and abdominal circumference at 36 months 
[24].These results suggest that early life exposure to parabens could potentially 
contribute to weight gain.  
 Adipocytes are derived from common multipotent mesenchymal stem cells that 
also give rise to osteocytes and chondrocytes [25]. Some EDCs are able to sensitize 
multipotent stem cells to undergo adipogenesis, but suppress their osteoblast 
differentiation [26]. The adipogenic effects of these EDCs were blocked by PPAR 
antagonist [26]. 
 In this study, we investigated effects of post-weaning exposure to parabens on 
metabolic biomarkers in mice fed with either a chow or a high fat diet. We have chosen 
methylparaben and butylparaben, since not only they are commonly used, but also they 
have the shortest and longest linear alkyl side chain, showing the weakest and strongest 
adipogenic activities in vitro [20]. We further investigated the effects of methylparaben 
and butylparaben on modulating cell fate using a multipotent stromal stem cell line 
C3H10T1/2.  We report here that post-weaning exposure to methylparaben increased 
body weight, body fat mass, and adiposity under a chow diet with low phytoestrogens. 
However, the effects were diminished under a high fat diet. Butylparaben exposure 
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showed only marginal effects. Moreover, both parabens modulated multipotent stem cell 
fate in vitro. Butylparaben markedly promoted adipogenic differentiation, but suppressed 
osteogenic and chondrogenic differentiation of C3H10T1/2 cells whereas methylparaben 
showed similar effects, but to a much less extent. 
3.4 Materials and methods 
Reagents 
Methylisobutylxanthine (MIX), dexamethasone (DEX), insulin (Ins), peroxisome 
proliferator-activated receptor gamma (PPARγ) agonist rosiglitazone were purchased 
from Sigma-Aldrich (St. Louis, MO). Methyl-, butylparaben (>=99%) and dimethyl 
sulfoxide (DMSO) were purchased from Acros Organics (Thermo Fisher Scientific, 
Pittsburg, PA). For animal treatment, parabens were dissolved in absolute alcohol at a 
concentration of 1.0 g/ml followed by dilution with corn oil to reach the final concentration 
of 10 mg/ml. The mice were then given 10 µl/g of body weight. For cell culture, parabens 
were dissolved in DMSO at a stock concentration of 100 mM.  The working 
concentration of parabens was 100 µM, which was obtained by diluting the stock with 
the culture medium (final concentration of DMSO was 0.1%).  
Animal husbandry and paraben treatment 
Female C57BL/6J mice (~3 weeks old) were purchased from the Jackson 
Laboratory (Bar Harbor, Maine). Mice were acclimated in our animal facility with 12 h 
light/dark cycle for one week.  Following acclimation, mice were lined up based on body 
weight and were randomly assigned to the vehicle control (corn oil), methylparaben, or 
butylparaben group (n=8 per group) so that each group had a similar average body 
weights. Mice were orally gavaged daily for 12 weeks with either corn oil, 
methylparaben, or butylparaben at 100 mg/kg/day, a level that is 10 times of the current 
recommended acceptable daily intake (ADI) for the sum of methylparaben, ethylparaben 
92 
 
and their sodium salts by European Food Safety Authority (EFSA).  During treatment,  
the mice were given ad libitum access to water and either a chow diet with minimal 
natural phytoestrogens (2020X) or a high-fat diet (45% kcal from fat, TD.120059) (Harlan 
laboratories, Madison, WI). Mice were terminated at 16 weeks of age. At termination, 
whole blood was collected by cardiac puncture and mice were euthanized by CO2. 
Various fat pads and the liver were isolated, weighed, and stored for histological and 
gene expression analysis. The animal procedures and protocols were approved by the 
Institutional Animal Care and Use Committee at the University of Tennessee Knoxville.  
Plasma and Serum measurements 
Plasma insulin was measured using Ultra Sensitive Mouse Insulin ELISA kit 
(Crystal Chem, Downers Grove, IL). Serum leptin and adiponectin were measured using 
Mouse Leptin ELISA Kit (Crystal Chem, Downers Grove, IL) and Mouse Adiponectin 
Quantikine ELISA Kit (R&D systems, Minneapolis, MN), respectively. Serum triglyceride 
was measured using kits from Wako (Wako Chemical USA, Richmond, VA). 
Glucose Tolerance and Insulin Tolerance Tests (GTT and ITT) 
The mice were given the GTT at 14 weeks and ITT at 15 weeks of age. For GTT, 
the mice were orally given a dextrose solution at 2 g/kg after an overnight fast. For ITT, 
the mice were intraperitoneally (Ip) injected with insulin (Humulin® R) (Lilly, Indianapolis, 
IN) at 0.75 U/kg after a 5 h fast. The blood glucose was measured at 0, 15, 30, 60, 90, 
120 min post the treatment with a handhold glucometer (LIFESCAN, Milpitas, CA). 
C3H10T1/2 cell culture and differentiation 
Multipotent stem cell line C3H10T1/2 (ATCC, Manassas, VA) were grown in 
Dulbecco's modified Eagle’s medium (DMEM) (Thermo Fisher Scientific, Waltham, MA) 
containing 10% fetal bovine serum (FBS) (Atlas Biologicals, Fort Collins, CO) in 5% CO2, 
37°C environment until confluence. Cells were differentiated into adipocytes, osteocytes,  
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Table 3.1 Ingredients of diets 
Diet 2020X TD. 120059 
Formula Ingredient g/kg Ingredient g/kg 
Crude Protein 
Fat (acid hydrolysis) 
Carbohydrate 
(available) 
Crude Fiber 
Neutral Detergent 
Fiber 
Ash 
 
191 
6.5 
 
470 
27 
123 
51 
Casein  
L-Cystine 
Sucrose 
Corn Starch 
Maltodextrin 
Anhydrous Milkfat 
Corn Oil 
Cellulose 
Mineral Mix, AIN-93G-
MX (94046) 
Vitamin Mix, AIN-93-VX 
(94047) 
Choline Bitartrate 
TBHQ, antioxidant 
Green Food Color 
195.0 
3.0 
340.0 
56.86 
60.0 
210.0 
20.0 
50.0 
 
43.0 
 
19.0 
3.0 
0.04 
0.1 
 
Selected Nutrition Information 
 % by weight % kcal 
from 
% by weight % kcal 
from 
Protein 
Carbohydrate 
Fat 
26.3 
65.9 
7.8 
24 
60 
16 
17.3 
47.6 
23.2 
14.8 
40.6 
44.6 
  
94 
 
or chondrocytes in the presence or absence of methylparaben or butylparaben (100 µM) 
as follows: 
Adipogenic differentiation  C3H10T1/2 cells were induced to differentiate using 
the standard 3T3-L1 differentiation protocol [27]. Briefly, on the day that the cells 
reached confluence (designated as day 0 or D0), cells were induced to differentiate with 
differentiation DMEM medium containing 10% FBS, 10 µg/ml insulin, 1 µM 
dexamethasone, and 0.5 mM 3-isobutyl-1-methylxanthine for 4 days. Cells were then 
switched to the maintenance DMEM containing 10% FBS and 10 µg/ml insulin for an 
additional 2 days followed by DMEM medium with 10% FBS for additional 2 days before 
the cells were harvested for analysis or oil red O staining. Parabens or the vehicle 
control (0.1% DMSO in culture medium) were applied at the induction and were 
reapplied at each change of the medium. 
Osteogenic differentiation  C3H10T1/2 cells were differentiated into osteocytes 
as described [28]. Briefly, the cells were plated at a density of 2x104/cm2, medium was 
replaced by fresh medium supplemented with 200 ng/ml of hBMP7 (R&D systems, 
Minneapolis, MI) 24 h later. Fresh medium with hBMP7 was replenished every two days 
until day 12. Parabens or the vehicle control (DMSO) were applied at the induction with 
hBMP7, and was reapplied at each change of the medium. 
Chondrogenic differentiation  C3H10T1/2 cells were differentiated into 
chondrocytes in a high-density mciromass culture as described [29]. Briefly, C3H10T1/2 
cells were trypsinized and resuspended in Ham’s F12K medium (CORNING, Tewksbury, 
MA) containing 10% FBS at a concentration of 107 
suspension were placed in the center of a well of 24-well tissue culture plates. Cells are 
allowed to adhere for 1-2 h at 37°C under 5% CO2, then 1 ml of medium containing 100 
ng/ml of hBMP2 (R&D systems, Minneapolis, MI) was added to the culture. Medium was 
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replenished every two days until day 6. Parabens or the vehicle control (DMSO) were 
applied at the induction with hBMP2, and was reapplied at each change of the medium. 
RNA preparation and quantitative real-time PCR analysis 
At indicated times, total RNA was prepared from C3H10T1/2 cells using TRI 
Reagent (Molecular Research Center, Inc., Cincinnati, OH) according to the 
manufacturer’s instruction. Total RNA abundance was quantified using a NanoDrop ND-
1000 Spectrophotometer (NanoDrop Technologies, Wilmington, DE). Reverse 
transcription was carried out using High Capacity Reverse Transcription kit (Applied 
Biosystems, Foster City, CA) according to the manufacturer’s instruction. mRNA 
expression of various genes, and the loading control 36B4 were measured by ABI 
7300HT quantitatively using gene-specific primers and SYBR master mix (Thermo 
Fisher Scientific). Cycle conditions were 50°C 2min, 95°C 15 min, then 40 cycles of 95°C 
for 15 s/60°C for 1 min. 
Oil red O (ORO) staining and quantification 
Lipid accumulation in differentiated adipocytes were stained with oil red O (ORO) 
and quantified by ORO absorbance, as previously described [20].  
Alkaline Phosphatase (ALP) staining 
C3H10T1/2 cells that have undergone osteocyte differentiation were washed with 
PBS and fixed with enough neutral buffered formalin (10%). After 60 seconds, the 
fixatives were removed and the cells were washed with washing buffer (PBS containing 
0.05% Tween 20). The cells were then covered by enough BCIP/NBT substrate solution 
(Thermo Fisher Scientific, Rockford, IL) and incubated at room temperature in the dark 
for 5-10 min. The staining progression was checked every 2-3 min.  When appropriate 
staining was achieved, the substrate solution was removed and the cells were washed 
and stored under PBS.  
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Alcian blue staining and quantification 
Chondrogenic differentiation was assessed as described [30]. Briefly, C3H10T1/2 
cells that have undergone chondrogenic differentiation were rinsed twice with PBS, and 
fixed in 4% (w/v) paraformaldehyde for 15 min. 1% (w/v) Alcian blue 8-GX (Sigma) in 0.1 
N HCl (pH 1.0) was applied to stain cells overnight. For quantitative analysis, 6 M 
guanidine HCl were used to recover the Alcian blue staining overnight at room 
temperature. Absorbance at 650 nm in the extracted dye was read in Glomax 
multidetection system (Promega, Madison, WI). 
Statistical analysis 
All data were presented as means ± SEM of each group (animal study) or 
triplicates (in vitro study). Statistical analysis was performed using SigmaPlot 12.5 
(Systat Software, Inc., San Jose, CA) with unpaired student’s t test. The level of 
significance was set at p < 0.05. 
3.5 Results 
Effects of post-weaning exposure to parabens on metabolic biomarkers in mice 
fed with a chow diet with low phytoestrogens. 
It is known that biological activities of EDCs in animal models are associated with 
many factors, such as strain and sex of animals examined, type of diet used and route of 
exposure [31-33]. In our studies, female obesity prone C57B6/J mice were orally 
gavaged for 12 weeks with the vehicle control (corn oil), methylparaben, or butylparaben 
at 100 mg/kg/day from weaning (4 weeks of age). We first investigated the effects of 
exposure under a chow diet with low phytoestrogens. Methylparaben-exposed mice 
were a little heavier than the control group and butylparaben-exposed mice, starting from 
one week of exposure. This trend continued until the end of the study at 16 weeks old. 
At termination, methylparaben-exposed mice were modestly but significantly heavier 
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(20.2±0.2 g) than the controls (19.4±0.3 g) (p<0.05); whereas there were no significant 
differences in body weight between butylparaben-exposed mice (19.0 ±0.3 g) and the 
controls (Fig. 3.1A). Further analysis revealed that methylparaben-exposed mice had a 
significant increase in total body fat mass by weight (0.82± 0.09 g) (p<0.05) and 
adiposity, as defined by adiposity index, i.e., percentage fat by weight (4.20±0.46 %), 
(p<0.05) compared with those of the controls (0.51±0.05 g; 2.70±0.25 %); no differences 
were observed between butylparaben-exposed mice and the controls in either body fat 
mass (0.54±0.03 g) or adiposity (2.97±0.15 %) (Fig. 3.1A). 
 Fasting glucose levels were not changed by methylparaben exposure (110±3 
mg/dL), but were significantly elevated in butylparaben-exposed mice (141±7 mg/dL) 
(p<0.05), compared with the controls (115±6 mg/dL) (Fig. 3.1B). No significant 
differences were observed in plasma insulin, or serum triglyceride levels among the 
groups. In contrast, mice exposed to methylparaben had elevated adiponectin 
(17.04±0.2 µg/ml) (p<0.05) and leptin concentration (5.50±0.50 ng/ml) (p<0.01) 
compared with the controls (15.88±0.44 µg/ml for adiponectin; 2.74±0.51 ng/ml for 
leptin).  No differences were observed between butylparaben-exposed mice (15.8±0.44 
µg/ml for adiponectin; 3.96±0.55 ng/ml for leptin) and the controls (Fig. 3.1B). 
 To further evaluate the glucose and insulin sensitivities, we performed glucose 
(GTT) and insulin tolerance tests (ITT). There were no significant differences among 
groups when area under the curves (AUC) were calculated and compared (Fig. 3.1C 
and 3.1D). 
 We further analyzed gene expression in white adipose tissue (WAT) and liver. 
Methylparaben-exposed mice had significantly increased mRNA expression of lipogenic 
marker FAS, SCD, and lipin 1 and leptin mRNA, but decreased adiponectin mRNA in the 
WAT (Fig. 3.2A). Butylparaben-exposed mice, on the other hand, had markedly   
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Figure 3.1 Effects of post-weaning exposure to parabens on body weight, body fat 
mass, adiposity and other metabolic biomarkers in mice fed with a chow diet with 
low phytoestrogens. 
Female C57B6/J mice were orally gavaged with the vehicle control, methyl- or 
butylparaben from weaning (4 weeks of age) for 12 weeks. Body weights were 
measured every week and at termination, whole blood was collected and white fat pads 
were isolated and weighed. (A) Body weights by week, body fat mass, adiposity index 
(body fat percentage) are shown. (B) After overnight fasting at termination, blood 
glucose, plasma insulin, serum triglyceride, adiponectin and leptin are shown. (C) 
Glucose tolerance tests and calculations of area under the curve (AUC). (D) Insulin 
tolerance tests and calculations of AUC. Data are mean ±SEM (n=8).  *,**, p<0.05 and 
p<0.01 versus the controls, respectively. 
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Figure 3.1 Continued 
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Figure 3.2 Effects of post-weaning exposure to parabens on gene expression in 
the WAT and liver in mice fed with the chow diet. 
(A) The WAT and (B) liver samples were isolated after termination, and were analyzed 
for relative gene expression. Expression was normalized to 36B4 and expressed as fold 
of the controls. Data are mean ±SEM (n=8).  *,**, p<0.05, and p<0.01 versus the 
controls, respectively.  
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increased mRNA expression of FABP4 and FAS in the WAT (Fig. 3.2A). We also 
examined lipogenic genes in the liver. Both methyl- and butylparaben-exposed mice had 
significantly decreased lipin 1 mRNA expression. Butylparaben-exposed mice also had 
decreased ADRP mRNA (Fig. 3.2B). 
Effects of post-weaning exposure to paraben on metabolic biomarkers in mice fed 
with a high fat diet. 
We further investigated the effects of post-weaning exposure to parabens in mice 
fed with a high fat diet. At termination, there were no significant differences in body 
weight among the groups (23.9±1.2 g for the control; 23.2±0.7 g for the methyl- group; 
and 24.5±0.7 g for the butyl- group) (Fig. 3.3A). No significant differences in the total 
body fat mass (1.89±0.31 g for the controls; 1.58±0.27 g for the methyl- group; and 
1.94±0.22 g for the butyl- group) and adiposity index (7.66±0.92 % for the control; 
6.60±0.96 % for the methyl- group; and 7.86±0.74 % for the butyl- group) were noted 
(Fig. 3.3A). Except for the plasma insulin levels, which were decreased in both methyl- 
(0.27±0.06 ng/ml) (p<0.01) and butylparaben-exposed mice (0.21±0.05 ng/ml) (p<0.01) 
compared to the controls (0.39±0.07 ng/ml), there were no significant differences in 
fasting glucose, serum triglyceride, adiponectin, and leptin levels among the groups (Fig. 
3.3B).  
 We also investigated the glucose and insulin sensitivities using GTT and ITT. We 
did not observe any significant differences in glucose tolerance tests among groups. 
However, at 15 min and 30 min, both paraben-exposed groups were more resistant to 
insulin compared to the controls (p<0.05), although the overall insulin sensitivities, as 
indicated by the AUC, were not significantly different among the groups (Fig. 3.3C and 
3.3D). 
 Gene expression analysis revealed that butylparaben-exposed mice had  
103 
 
Figure 3.3 Effects of post-weaning exposure to parabens on body weight, body fat 
mass, adiposity and other metabolic biomarkers in mice fed with a high fat diet.  
Female C57B6/J mice were orally gavaged with the vehicle control, methyl- or 
butylparaben from weaning (4 weeks of age) weaning (4 weeks of age) for 12 weeks. 
Body weights were measured every week and at termination, whole blood was collected 
and white fat pads were isolated and weighed. (A) Body weights by week, body fat 
mass, adiposity index (body fat percentage) are shown. (B) After overnight fasting at 
termination, blood glucose, plasma insulin, serum triglyceride, adiponectin and leptin are 
shown. (C) Glucose tolerance tests and calculations of area under the curve (AUC). (D) 
Insulin tolerance tests and calculations of AUC. Data are mean ±SEM (n=8).  #, *, 
p<0.05 for methyl- and butylparaben relative to the controls at the same time points, 
respectively. 
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decreased adiponectin and increased lipin 1 mRNA expression in WAT (Fig. 3.4A). On 
the other hand, methylparaben-exposed mice had decreased perilipin (PLIN) mRNA 
expression (Fig. 3.4A). In the liver, mRNA expression of lipogenic FAS and lipin 1 were 
increased in butylparaben-exposed mice whereas methylparaben-exposed mice didn’t 
show any differences in mRNA of the genes examined (Fig. 3.4B). 
Effects of parabens on adipogenic differentiation of multipotent stem cell 
C3H10T1/2. 
The findings that post-weaning exposure to parabens, methylparaben in 
particular, increased adiposity promoted us to examine the modulation of stem cell fate 
by parabens. We examined the effects of methyl- and butylparaben on modulation of cell 
fates using a multipotent stem cell line C3H10T1/2, which has the potentials to be 
differentiated into adipocytes, osteocytes, or chondrocytes [34]. First, we examined the 
effects of parabens on adipogenic differentiation of C3H10T1/2 cells. After 12 h 
treatment, both methyl- and butylparaben significantly suppressed Runx2 mRNA 
expression by 35% (p<0.05) and 40% (p<0.05), respectively (Fig. 3.5A). Runx2 is a 
transcription factor, whose expression is down-regulated in adipogenic differentiation, 
but up-regulated in both osteogenic and chondrogenic differentiation of C3H10T1/2 cells. 
Butylparaben significantly induced PPARand C/EBP mRNA expression by 70% 
(p<0.01) and 130% (p<0.01), respectively (Fig. 3.5A). Methylparaben only increased 
C/EBP mRNA expression by 30% (p<0.01) (Fig. 3.5A). We further investigated whether 
the transcriptional modulation by parabens at early stage lead to differences in terminal 
differentiation. On day 8, butylparaben treatment increased mRNA expression of 
adipocyte marker gene PPARby100% (p<0.05) C/EBPby 150% (p<0.01), FABP4 by 
75% (p<0.01) compared to the DMSO controls (Fig. 3.5A), demonstrating an enhanced 
adipogenic differentiation, which was consistent with ORO stained cell morphology and  
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Figure 3.4 Effects of post-weaning exposure to parabens on gene expression in 
the WAT and liver in mice fed with the high fat diet.  
(A) The WAT and (B) liver samples were isolated after termination, and were analyzed 
for relative gene expression. Expression was normalized to 36B4 and expressed as fold 
of the controls. Data are mean ± SEM (n=8).  *,**, p<0.05, and p<0.01 versus the 
controls, respectively. 
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Figure 3.5 Effects of parabens on adipogenic differentiation of multipotent stem 
cell C3H10T1/2.  
C3H10T1/2 cells were induced for adipogenic differentiation in the presence or absence 
of methyl-, butylparaben or the vehicle control DMSO. (A) mRNA expression of Runx2, 
PPAR, and C/EBP were analyzed at 12 h after the initiation of differentiation. mRNA 
expression of PPAR, C/EBPand FABP4 were analyzed on day 8 after the initiation. 
Expression was normalized to 36B4 and expressed as fold of the controls (set at 1). (B) 
Oil red O (ORO) staining of cell morphology at day 8 and quantifications of ORO 
absorbance were shown. Data are mean ± SEM (n=3).  *,**, p<0.05 and p<0.01 versus 
the vehicle control DMSO, respectively. 
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quantifications of ORO absorbance (Fig. 3.5B). Methylparaben, however, didn’t show 
noticeable enhancement on terminal adipogenic differentiation of C3H10T1/2 cells (Fig. 
3.5A and 3.5B). 
Effects of parabens on osteogenic differentiation of C3H10T1/2 cells. 
 Next, we examined the effects of parabens on osteogenic differentiation of 
C3H10T1/2 cells. After 12 h treatment, methyl- and butylparaben significantly 
suppressed Runx2 mRNA expression by 20% (p<0.05), and 30% (p<0.01), respectively 
(Fig. 3.6A). Consistently, both methyl- and butylparaben suppressed mRNA expression 
of osteogenic marker gene alkaline phosphatase (ALP) by 40% (p<0.01) at day 12.  
Methyl- and butylparaben suppressed mRNA of osteocalcin (OCA) by 25% (p<0.05) and 
80% (p<0.01), respectively, and suppressed osteopontin (OPN) by 20% (p<0.05) and 
30% (p<0.01), respectively (Fig. 3.6A). ALP staining in differentiating cells revealed 
marked suppression of staining by butylparaben and modest suppression by 
methylparaben (Fig. 3.6B). Microscopic images at day 12 revealed a strong suppression 
of differentiation by butylparaben and modest suppression by methylparaben compared 
with the well differentiated controls (Fig. 3.6C). 
Effects of parabens on chondrogenic differentiation of C3H10T1/2 cells. 
 Lastly, we examined the effects of parabens on chondrogenic differentiation of 
C3H10T1/2 cells. After 12 h treatment, methyl- and butylparaben suppressed Runx2 
mRNA expression of by 40% (p<0.01) and 30% (p<0.01), respectively. Consistently, 
both suppressed collagen type II (Col II) by 40% (p<0.01), and suppressed collagen type 
X (Col X) by 40% (p<0.01) and 50% (p<0.01), respectively (Fig. 3.7A). Aggrecan (Agg) 
mRNA expression was not changed by either paraben at this time point (data not 
shown). At day 6, butylparaben abolished Agg mRNA expression by almost 100% 
(p<0.01), Col II by 95% (p<0.01), and Col X by 40 % (p<0.01) (Fig. 3.7A) compared with   
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Figure 3.6 Effects of parabens on osteogenic differentiation of multipotent stem 
cell C3H10T1/2.  
C3H10T1/2 cells were induced for osteogenic differentiation in the presence or absence 
of methyl-, butylparaben, or the vehicle control DMSO. (A) mRNA of Runx2 was 
analyzed at 12 h and mRNA expression of ALP, OCA and OPN were analyzed on day 
12 after the initiation of differentiation. Expression was normalized to 36B4 and 
expressed as fold of the controls (set at 1). Data are mean ± SEM (n=3).  *,**, p<0.05 
and p<0.01 versus the vehicle control DMSO, respectively. (B) ALP staining of the 
differentiating cells were performed on day 2. (C) Microscopic images of the cells at day 
12 were shown.   
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Figure 3.7 Effects of parabens on chondrogenic differentiation of multipotent stem 
cell C3H10T1/2.  
Micromass of C3H10T1/2 cells were seeded and induced for chondrogenic 
differentiation in the presence or absence of methyl-, butylparaben, or the vehicle control 
DMSO. (A) mRNA expression of Runx2, Agg, Col II and Col X were analyzed at 12 h 
and day 6 after initiation of differentiation. Expression was normalized to 36B4 and 
expressed as fold of the controls (set at 1). (B) Alcian blue staining and quantifications of 
the absorbance were performed on day 6. Data are mean ± SEM (n=3).  **, p<0.01 
versus the vehicle control DMSO. (C) Microscopic images of the micromass at day 6 
were shown. 
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the DMSO control. Methylparaben did not show any noticeable effects on mRNA of 
these marker genes. The effects were confirmed by Alcian blue staining of the 
differentiated cells and by the quantifications of the absorbance of the staining (Fig. 
3.7B). Microscopic images revealed a large portion of undifferentiated cells in the 
peripheral of the micromass by butylparaben and a much smaller portion of 
undifferentiated cells in the peripheral by methylparaben compared with the DMSO 
controls (Fig. 3.7C). 
3.6 Discussion 
Parabens are widely used as preservatives in personal care products, cosmetics, 
toiletries, pharmaceuticals and foods. Based on the industry estimates of the daily use of 
cosmetics and assumption that parabens are used at the highest permissible 
concentration (0.8%), it was estimated that daily dose of total parabens from cosmetics 
is 142.08 mg and 3.024 mg for adults and infants, respectively. The paraben dose for an 
adult weighing 60 kg is then equaled to 2.368 mg/kg body weight/day. Widespread 
production and use of parabens have resulted in wide detections of parabens in 
environmental samples, such as surface water, soils, sediments and sludge, air and 
dust, and even in fish meat, which could presumably get into human body through oral 
ingestion and inhalation (reviewed in Bledzka et al 2014). To this end, it has been 
reported that almost all common foodstuffs in China contained at least one of the 
parabens analyzed, although the concentrations of parabens reported were generally 
low in those foods [2]. Our exposure of parabens was set at 100 mg/kg/day, which is 10 
times of the current recommended acceptable daily intake (ADI) for the sum of 
methylparaben, ethylparaben and their sodium salts by European Food Safety Authority 
(EFSA). This dose seems to be relevant and consistent with others reported in in vivo 
rodent studies [11,15-17]. Due to the non-monotonic dose-response relationship 
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reported for some known EDCs, such as bispenol A (BPA), studies that use a range of 
doses of parabens are needed in the future.  
 Studies on the effects of parabens have mostly been focused on reproductive 
systems [15-17]. To the best of our knowledge, our study is the first to investigate the 
adipogenesis, associated metabolic consequences of paraben exposure, and their 
interactions with diet in vivo. Notably, methylparaben had more apparent effects than 
butylparaben in increasing body fat mass, adiposity, and serum leptin in mice fed with 
the chow diet, compared with the controls. This is in contrast to the fact that 
methylparaben was much less effective than butylparaben in promoting adipogenesis in 
vitro [20]. Following oral administration, parabens are known to be subjected to 
hydrolysis by widely distributed, non-specific esterase in the gastrointestinal tract and 
liver. It has been reported that efficiency and pattern of hydrolysis of parabens vary 
considerably depending on the alkyl chain length and tissue [35,36]. The hydrolytic 
activity of human carboxylesterase 2 (hCE-2), the predominant form found in human 
small intestine, increases with the increasing length of the alkyl chain of paraben esters 
[36]. Similarly, butylparaben seemed to be more effectively hydrolyzed by the 
microsomes from the rat liver and the small intestine, compared to parabens with shorter 
alkyl side chain [35]. Therefore, our findings that more apparent effects were observed in 
methylparaben-exposed mice may be due to more parental methylparaben available in 
the exposed mice. Notably, even though butylparaben had no significant effects on body 
weight, adiposity, and serum adipokines, it significantly increased fasting glucose levels 
(Fig. 3.1B) and mRNA expression of some adipogenic markers, such as FABP4 and 
FAS in the WAT in mice fed with the chow diet (Fig. 3.2A), suggesting that some tissues, 
such as the liver, insulin-secreting pancreatic exocrine cells (the former two organs are 
important for regulating fasting glucose levels), and stromal stem cells in the WAT, 
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capable of becoming mature fat cells, may be more sensitive to a presumably low 
concentration of butylparaben.  
 Interactions of diet with EDC exposure have been reported. While perinatal 
exposure to BPA increased body weight and impaired glucose tolerance in adult 
offspring rats fed with normal diet, high fat feeding (28.5% kcal from fat) further 
accelerated and exacerbated the detrimental effects [31]. In another study, male adult 
rats exposed to BPA displayed impairment of glucose homeostasis under regular chow 
diet, and the disruption was aggravated by high fat diet (41.3% kcal from fat) [37]. 
However, several endpoints, such as serum insulin level and HOMA-IR at 35 weeks, 
showed more pronounced differences by BPA exposure under the chow diet than under 
a high fat diet [37]. In our study we used a high fat diet with 45% kcal from fat with lipid 
profiles mimicking a western diet. The high fat feeding did not synergize with the effects 
of paraben exposure. In contrast, many effects observed in methylparaben-exposed 
mice under the chow diet were attenuated by the high fat diet. Future studies with diets 
with a lower range of kcal from fat may provide additional information on the interaction 
of paraben exposure with diet. 
 There is a general consensus that perinatal periods (i.e., during gestation and 
lactation) are sensitive window of development, most susceptible to nutritional and 
environmental insults and the influences occur during early development can impact 
health later in life. This is often referred as “developmental origins of health and disease” 
(DoHAD) paradigm. Studies of exposure of pregnant dams to ethyl- or butylparaben 
from gestational day 7 to 21 revealed that parabens can cross the placenta, and 
concentrate in the fetuses, resulting in higher concentrations of free and glucuronidated 
and sulfated parabens in the embryonic fluid, fetal carcass and fetal liver than in the 
maternal plasma [11]. We have used a post-weaning exposure model to investigate the 
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adipogenic effects of paraben exposure in vivo in the current studies. Our findings from 
the post-weaning exposure have provided additional rationales to study the effects of 
perinatal exposure of parabens. Therefore, further studies on the effects of perinatal 
exposure to parabens on the development of obesity and metabolic dysfunction in later 
life are warranted. 
 Multipotent stem cell C3H10T1/2, which possess the potential to be differentiated 
into adipocytes, chondrocytes, osteocytes or myocytes [34], has been widely used as a 
model to study the alteration of stem cell fate. Consistent with potent effects on 3T3-L1 
adipocyte differentiation [20], butylparaben markedly enhanced adipogenic differentiation 
of C3H10T1/2 cells. Methylparaben suppressed Runx2, but up-regulated C/EBPα, not 
PPAR at the early time point, but it did not enhance adipogenic differentiation at day 8. 
In contrast, butylparaben markedly suppressed differentiation of osteoblasts and 
chondrocytes from C3H10T1/2 whereas methylparaben suppressed osteogenic 
differentiation to a much lesser degree and had minimal effects on chondrogenic 
differentiation (Fig. 3.6 and 3.7). Our results suggest that increased adiposity with 
modestly increased gross body weight by post-weaning exposure to parabens, 
methylparaben in particular, may be attributed to the modulation of multipotent stem cell 
fate by parabens. 
 The mechanisms by which parabens modulate stem cell fates are not clear at 
this point. It has been reported that tributyltin (TBT), an EDC mostly found in seafood 
and food crops from the use of TBT as an antifouling agents on boats and fungicides, 
sensitized adipose-derived mulitpotent stem cells (MSC) to differentiate into adipocytes 
while suppressing their osteogenic differentiation [26]. TBT was shown to be an agonist 
of PPAR, a known master transcription factor controlling adipocyte differentiation. It is 
thought that the effects of TBT were mediated through PPAR. Overexpression of 
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PPAR2 stimulated adipocyte marker FABP4 expression and fat accumulation in murine 
bone marrow-derived stem cells, while suppressing Runx2 expression and osteogenic 
differentiation [38]. Activation of PPAR by its ligand in mesenchymal cells inhibited the 
expression of osteocalcin, an osteoblast specific protein, both by suppressing the 
expression and the transactivation ability of Runx2 [39]. Transcription factor Runx2, 
which belongs to the runt-domain gene family, is highly expressed in osteoblasts and 
chondrocyte and its up-regulation is required for differentiation of osteoblasts [40,41,28] 
and chondrocytes [42,43]. In contrast, Runx2 has been shown to be an inhibitor for 
adipocyte differentiation and its down-regulation promotes adipocyte differentiation [44]. 
Moreover, Runx2 has been identified as a downstream target of glucocorticoid receptor 
(GR) signaling as Runx2 mRNA was suppressed by the synthetic glucocorticoid 
dexamethasone, a key component of adipogenic cocktail, during adipocyte 
differentiation [44]. Since parabens have been reported to activate both GR and PPAR, 
it is possible that parabens could modulate stem cell fate through down-regulating 
Runx2 expression downstream of GR and/or PPAR activation. Consistently, we have 
found that both parabens down-regulated Runx2 during differentiation of adipocytes, 
osteoblasts and chondrocytes of C3H10T1/2 (Fig. 3.5, 3.6 and 3.7). Future studies are 
necessary to confirm the role of Runx2 in the modulation of stem cell fates by parabens.  
 In conclusion, we show that parabens, methylparaben in particular, increase 
adiposity in mice fed with the chow diet, possibly through modulation of multipotent 
mesenchymal stem cell fate towards adipose lineage at the expense of osteoblast and 
chondrocyte lineage. Our studies have provided additional rationales to study paraben 
exposure at a range of doses and during the perinatal period, a presumably more 
sensitive window of development, in the future. 
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CONCLUSION AND FUTURE DIRECTIONS 
Conclusion 
In this dissertation, we have shown that parabens promote adipocyte 
differentiation in murine 3T3-L1 cells, which might be mediated through activation of 
nuclear receptor PPAR and/or GR. The adipogenic potency of parabens is increased 
with increasing length of the linear alkyl chain in following potency ranking order: methyl- 
< ethyl- < propyl- < butylparaben. Benzylparaben has an aromatic ring and preserves 
strong adipogenic potency; the common metabolite of all parabens 4-hydroxybenzoic 
acid, and the structurally related benzoic acid are inactive in promoting 3T3-L1 adipocyte 
differentiation. We find that parabens, butyl- and benzylparaben in particular, can 
promote adipose conversion of human adipose-derived multipotent stromal cells. We 
demonstrate that exposure to methyl- and butylparaben in female C57B6/J mice 
increased adiposity and altered metabolic markers. Both parabens showed effects on 
modulating stem cell fates, and butylparaben is more potent in promoting adipocyte 
differentiation but suppressing differentiation of osteocytes and chondrocytes from 
C3H10T1/2 cells. We conclude that parabens exposure could increase adiposity through 
enhancing differentiation of predetermined preadipocytes, as well as through modulating 
the multipotent stem cells towards adipose lineage at the expense of osteocyte and 
chondrocyte lineage. 
Future Directions 
Obesity might be resulted from events taking place early in life, such as during 
gestation and postnatal development when individuals are exposed to various EDCs 
including parabens. In an attempt to explore the possible effects of paraben exposure on 
adipogenesis we have performed studies both in vitro and in vivo.  
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We have shown that parabens enhance adipocyte differentiation in murine cell 
line 3T3-L1, which is possibly mediated though activation of GR. EDCs have been 
shown to modulate GR activity by completing with the ligand binding to the receptor, but 
the GR competitor assays in our study didn’t show signs of competitive binding of GR by 
parabens, nor did it show that. Parabens modulate ligand binding of GR. Some EDCs 
have been shown to modulate GR activation by working on glucocorticoid metabolizing 
enzymes (such as 11-HSD1 and 2), but our preliminary study didn’t provide sufficient 
evidence to support this hypothesis. Future studies on the mechanisms by which 
parabens modulate GR activation are needed to elucidate the roles of parabens in 
promoting adipogenesis. 
Butylparaben showed much stronger adipogenic potency than methylparaben 
when used in 3T3-L1 cells. For the animal study, we have chosen methyl- and 
butylparaben since these two parabens are commonly used and they bracket the length 
of the linear alkyl side chain. However, we found more significant homeostasis disruption 
caused by methylparaben in mice, and butylparaben only had marginal effects. Since 
parabens are subject to hydrolysis by esterase after oral administration, the abilities of 
parabens to escape the hydrolysis might be the key to explain the discrepancies 
between in vitro vs in vivo we observed. Future studies on the hydrolysis efficiency of 
different esterases on specific parabens are needed to further validate the results of our 
in vivo studies.  
Runx2 belongs to runt-domain gene family and is highly expressed in mature 
osteoblasts and chondrocytes. Up-regulation of Runx2 is required for differentiation of 
osteoblasts and chondrocytes, while its down-regulation promotes adipogenic 
differentiation. We have shown that both methyl- and butylparaben suppressed Runx2 
expression at the early stage in adipogenic, osteogenic, and chondrogenic differentiation 
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of C3H10T1/2 cells. In-depth mechanistic study on how parabens work on Runx2 
expression and its transcriptional activity would provide us with more insight into the 
mechanisms by which parabens induce adiposity in vivo.  
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